

**(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE**

(11) Application No. AU 2008279619 B2

**(54) Title
Antibodies to CD200 and uses thereof in inhibiting immune responses**

(51) International Patent Classification(s)
C07K 16/28 (2006.01) A61K 39/395 (2006.01)
A61K 31/445 (2006.01) A61P 37/06 (2006.01)
A61K 38/13 (2006.01)

(21) Application No: 2008279619 (22) Date of Filing: 2008.07.25

(87) WIPO No: WO09/014745

(30) Priority Data

(31) Number (32) Date (33) Country
60/962,022 2007.07.25 US

**(43) Publication Date: 2009.01.29
(44) Accepted Journal Date: 2013.11.14**

**(71) Applicant(s)
Alexion Pharmaceuticals, Inc.**

**(72) Inventor(s)
Faas McKnight, Susan;Rother, Russell P.**

**(74) Agent / Attorney
Shelston IP, L 21 60 Margaret St, Sydney, NSW, 2000**

**(56) Related Art
WO 2007/084321 A2**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



PCT

(43) International Publication Date
29 January 2009 (29.01.2009)

(10) International Publication Number
WO 2009/014745 A1

(51) International Patent Classification:

A61K 39/395 (2006.01) *A61P 37/06* (2006.01)
A61K 38/13 (2006.01) *C07K 16/28* (2006.01)
A61K 31/445 (2006.01)

06712 (US). FAAS MCKNIGHT, Susan [US/US]; 14 Stonewood Drive, Old Lyme, CT 06371 (US).

(21) International Application Number:

PCT/US2008/009037

(22) International Filing Date: 25 July 2008 (25.07.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/962,022 25 July 2007 (25.07.2007) US

(71) Applicant (for all designated States except US): ALEXION PHARMACEUTICALS, INC. [US/US]; 352 Knoter Drive, Cheshire, CT 06410 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ROTHER, Russell, P. [US/US]; 25 Blue Trail Drive, Prospect, CT

(74) Agents: VARMA, Anita et al.; ROPES & GRAY LLP, One International Place, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.



(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL,

[Continued on next page]

(54) Title: ANTIBODIES TO CD200 AND USES THEREOF IN INHIBITING IMMUNE RESPONSES

FIGURE 6

Human T cells activated through T cell receptor signaling serve as sensitive targets for anti-CD200 mediated ADCC



(57) Abstract: This disclosure provides methods and compositions for inhibiting immune responses by inhibiting the interaction between CD200 and CD200R. The disclosure also provides methods and compositions for inhibiting graft rejection and promoting or prolonging graft survival by inhibiting the interaction between CD200 and CD200R.

WO 2009/014745 A1



NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

Published:

— *with international search report*

ANTIBODIES TO CD200 AND USES THEREOF IN INHIBITTING IMMUNE RESPONSES**RELATED APPLICATIONS**

This application claims the benefit of U.S. Provisional Application No. 60/962,022, filed July 25, 2007, which application is hereby incorporated by reference in its entirety.

TECHNICAL FIELD

The disclosure relates to OX-2/CD200 (herein referred to as CD200) binding agents and methods of preventing or inhibiting an immune response. The compositions and methods described herein may be used to treat patients with autoimmune disorders and graft recipients. The methods of therapy for promoting tolerance of grafts include administering a CD200-binding agent, such as an anti-CD200 antibody, to a transplant or graft recipient, thereby prolonging survival of the graft.

BACKGROUND

Immune cells help attack and eliminate foreign invaders such as infectious agents. However, in certain instances, such as in autoimmune disorders, allergies, and the rejection of tissue or organ transplants, the immune system can be the cause of illness. In transplantation of a graft (e.g., a cell, a tissue, or an organ) from a donor to a recipient, the recipient's immune reaction to the graft causes illness. Nevertheless, transplantation of cells, tissues and organs is very common and is often a life-saving procedure. Organ transplantation is the preferred treatment for most patients with chronic organ failure. Despite great improvement in treatments to inhibit immune rejection of a transplant (i.e., graft rejection), this rejection—which includes both acute and chronic rejection—continues to be the single largest impediment to successful organ transplantation. One-year survival rates for renal transplants, for example, average 88.3% with kidneys from deceased donors and 94.4% with kidneys received from living donors. The corresponding five-year survival rates for the transplanted kidneys are 63.3% and 76.5% (OPTN/SRTR Annual Report, 2002. Chapter 1 of the Annual Report produced by the Scientific Registry of Transplant

Recipients (SRTR) in collaboration with the Organ Procurement and Transplantation Network (OPTN). See world wide web at unos.org/data/ar2002/ar02_chapter_one.htm). For liver transplants, the one- year survival rates are 80.2% and 76.5% for livers from deceased and living donors, respectively. The corresponding five-year liver graft survival rates are 63.5% and 73.0% (OPTN/SRTR Annual Report, 2002. Chapter 1 of the Annual Report produced by the Scientific Registry of Transplant Recipients (SRTR) in collaboration with the Organ Procurement and Transplantation Network (OPTN). See world wide web at unos.org/data/ar2002/ar02_chapter_one.htm). The use of immunosuppressant drugs, especially cyclosporine A and more recently tacrolimus, has dramatically improved the success rate of organ transplantation. These agents have especially been successful in inhibiting acute rejection. Yet, as the numbers above show, there is still a need to improve both the short-term and especially the long-term survival rates following transplantation.

There are multiple types of transplants. A graft transplanted from one individual to the same individual is called an autologous graft or autograft. A graft transplanted between two genetically identical or syngeneic individuals is called a syngeneic graft. A graft transplanted between two genetically different individuals of the same species is called an allogeneic graft or allograft, and a graft transplanted between individuals of different species is called a xenogeneic graft or xenograft.

Currently more than 40,000 kidney, heart, lung, liver and pancreas transplants are performed in the United States each year (Abbas et al., 2000; Cellular and Molecular Immunology (4th edition), p. 363-383 (W.B. Saunders Company, New York). Other possible transplants include, but are not limited to, vascular tissue, eye, cornea, lens, skin, bone marrow, muscle, connective tissue, gastrointestinal tissue, nervous tissue, bone, stem cells, islets, cartilage, hepatocytes, and hematopoietic cells. Unfortunately, there are many more candidates for a transplant than there are donors. To overcome this shortage, a major effort is being made to learn how to use xenografts. While progress is being made in this field, at present most transplants are allografts.

In transplantation, therefore, the donor's genetic background is often different from the genetic background of the recipient (e.g., allotransplantation), and the donor

and recipient thus differ in their histocompatibility antigens, i.e., antigens of the major histocompatibility complex (MHC), called the HLA system in humans. The recipient therefore recognizes the graft as a foreign substance, and various immune responses work to reject and eliminate the graft. Graft rejection refers to the immune responses of the recipient against the graft. The immune responses that act in graft rejection can be classified into (1) hyper-acute rejection, which is a strong rejection occurring immediately after transplantation; (2) acute rejection, which is observed within a few months after transplantation (also included is acute vascular rejection such as accelerated humoral rejection and *de novo* acute humoral rejection); and (3) chronic rejection observed several months after transplantation. Rejection is normally a result of T-cell mediated and/or humoral antibody attack, but may include additional secondary factors, cytokines and other immune cells such as macrophages. The molecules that the recipient's immune cells recognize as foreign on allografts are called alloantigens and these molecules on xenografts are called xenoantigens. The recipient's lymphocytes or antibodies that react with alloantigens or xenoantigens are described as being alloreactive or xenoreactive, respectively.

Cellular immunity (due to immunocompetent cells represented by T cells) and humoral immunity (due to antibodies) work in an intricately coordinated manner in graft rejection (see Rocha et al. 2003 *Immunol. Rev.* 196: 51-64). T cell responses to antigens from the donor organ are generally acknowledged to mediate acute rejection. In allotransplantation, CD8+ cytotoxic T cells recognize donor MHC molecules expressed on the allograft and/or on leukocytes (i.e., antigen-presenting cells) within the graft. In cases in which the allograft differs from the recipient at both class I and class II sites, recognition of the MHC molecules leads to activation of both CD8+ and CD4+ T cells. While allogeneic MHC antigens provide one signal to stimulate CD4+/T helper cells of the recipient, recipient macrophages provide a second signal, interleukin 1 (IL-1), which is essential to the activation of T helper cells. Activated T helper cells produce IL-2, which leads to the proliferation of cytotoxic T cells and lymphokine-activated killer cells and the release of IL-4 and IL-6. In addition, IL-2 promotes release of interferon gamma as well as tumor necrosis factor and other proinflammatory cytokines.

APCs (antigen-presenting cells, e.g., dendritic cells) are also involved in graft rejection, as mentioned above. Allograft and xenograft antigens can be processed and presented indirectly by recipient APCs, which may infiltrate the graft. Recipient APCs presenting donor antigens are transported to lymph nodes through the circulation, where they activate T cells. APC activity leads to lymphocyte proliferation and eventual T cell infiltration into the donor graft.

Another immune response in graft rejection is the production of anti-donor antibodies (such as alloantibodies in the case of an allograft), which is mediated by B-cells. This response, however, requires the activity of CD4+ T cells that stimulate B-cell growth, differentiation, and secretion of antibodies. Binding of alloantibodies to MHC antigens expressed on endothelial cells activates a complex response involving the complement and coagulation pathways, which ultimately results in inflammation and graft injury. Alloantibodies can also mediate antibody-dependent cellular cytotoxicity (ADCC) via the Fc region of the antibody molecule. The activities of alloantibodies and complement may be important for hyperacute, acute humoral, and chronic rejection of a graft, and alloantibodies to donor HLA class I or class II antigens have been associated with chronic rejection of various transplanted organs.

As a result of graft rejection, the graft ultimately becomes necrotic. Furthermore, the recipient develops not only severe systemic symptoms such as fever, leukocytosis and fatigue, but also swelling and tenderness at the transplantation site. Severe complications such as infections may also occur.

A limited number of immunosuppressive agents that suppress the function of immunocompetent cells are used to suppress graft rejection. Such immunosuppressive agents include cyclosporine (CsA); tacrolimus (FK-506); azathioprine (AZ); mycophenolate mofetil (MMF); mizoribine (MZ); leflunomide (LEF); adrenocortical steroids (also known as adrenocortical hormones, corticosteroids, corticoids) such as prednisolone and methylprednisolone; sirolimus (also known as rapamycin); deoxyspergualin (DSG); and FTY720 (also called Fingolimod, chemical name: 2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol hydrochloride). Also being clinically developed as immunosuppressive agents are agents that block CTLA-4 and CD28, which are molecules responsible for transducing costimulatory signals necessary for the activation of T cells

(costimulatory signal transduction molecules); such agents include CTLA-4 drugs that use the soluble region of CTLA-4 and the gene encoding it.

General immunosuppressives, such as corticosteroids and cytokine antagonists, can elicit undesirable side effects including toxicity and reduced resistance to infection. Thus, alternative, and perhaps more specific, methods of treating autoimmunity and promoting graft survival are needed.

One molecule that has been thought to induce immunosuppression and promote graft survival is OX-2, or CD200. CD200 is expressed on the surface of B cells, some T cells, dendritic cells and other cells and possesses a high degree of homology to molecules of the immunoglobulin gene family. CD200 has been implicated in immune suppression, and it has been shown, for example, that CD200-expressing cells can inhibit the stimulation of Th1 cytokine production (Gorcynski et al., 1998 *Transplantation* 65:1106-1114). In addition, soluble CD200 has been shown to promote allo- and xenograft survival in mice and to decrease antibody response to sheep erythrocytes in mice (Gorcynski et al. 1999 *J. Immunol.* 163: 1654-1660). Further, CD200-knockout mice exhibit a decreased ability to down-regulate APC activation compared to wildtype mice, resulting in chronic inflammation in the central nervous system, a hyper-inflammatory response, and increased susceptibility to certain experimental autoimmune disorders (Hoek et al. 2000 *Science* 290: 1768-1771). The immunosuppressive effects of CD200 are believed to be the result of CD200 binding to its receptor, CD200R (Hoek et al. *supra*; Gorczynski et al. 2000 *J. Immunol.* 165: 4854), which is expressed on cells of monocyte/myeloid lineage and of T-lymphocyte origin.

While CD200 has been shown to elicit immunosuppressive effects, an antibody to CD200 has been shown to inhibit these immunosuppressive effects. For example, an anti-CD200 antibody (including an anti-CD200 F(ab')₂ fragment) abolished the CD200Fc-induced prolonged survival of rat islet xenografts in mice (Gorcynski et al. 2002 *Transplantation* 73: 1948-53).

Contrary to the published reports discussed above, the present disclosure demonstrates that an anti-CD200 antibody and compositions comprising an anti-CD200 antibody promote graft survival. Accordingly, the present disclosure provides

novel compositions and methods for inhibiting graft rejection and promoting graft survival.

Any discussion of the prior art throughout the specification should in no way be considered as an admission that such prior art is widely known or forms part of common general knowledge in the field.

It is an object of the present invention to overcome or ameliorate at least one of the disadvantages of the prior art, or to provide a useful alternative.

SUMMARY

The present disclosure relates to the discovery that administration of an anti-CD200 antibody can inhibit immunological responses to an immune challenge, such as a grafted tissue or organ. In certain embodiments, the present disclosure provides methods and pharmaceutical agents to suppress, treat, or prevent immunological responses, where in particular embodiments the immunological response accompanies the transplantation of a cell, tissue, or organ (e.g., graft rejection or graft versus host disease). Also, the immunological response may occur at a later time, e.g., during a rejection episode in the recipient of a transplanted cell, tissue or organ. The methods and agents of the disclosure may employ medical and pharmaceutical techniques (for example, pharmaceutical agents such as low-molecular weight compounds and antibodies) to modulate the biological function of CD200 or to modulate the activity of cells expressing CD200.

According to a first aspect, the present invention provides a method of inhibiting an immune response in a subject in need thereof, wherein said method comprises administering to the subject an effective amount of i) an agent which inhibits interaction between CD200 and CD200R and ii) an immunosuppressive or immunomodulatory drug, wherein said agent is an antibody, or an antigen-binding fragment thereof, which (a) binds to CD200 and (b) exhibits reduced ADCC or CDC activity or no ADCC or CDC activity.

According to a second aspect, the present invention provides a method of decreasing what constitutes an effective amount of an immunosuppressive or

immunomodulatory drug administered to a subject, said method comprising administering to said subject i) said immunosuppressive or immunomodulatory drug and ii) an agent which inhibits interaction between CD200 and CD200R, wherein less of said drug is required to effect immunosuppression or immunomodulation as compared to administering said drug without said agent, and wherein said agent is an antibody, or an antigen-binding fragment thereof, which (a) binds to CD200 and (b) exhibits reduced ADCC or CDC activity or no ADCC or CDC activity.

According to a third aspect, the present invention provides a method of inhibiting rejection of an allograft in an allograft recipient during a rejection episode, said method comprising administering to said allograft recipient an effective amount of an agent which inhibits interaction between CD200 and CD200R, wherein rejection of said allograft is inhibited, and wherein said agent is an antibody, or an antigen-binding fragment thereof, which (a) binds to CD200 and (b) exhibits reduced ADCC or CDC activity or no ADCC or CDC activity.

According to a fourth aspect, the present invention provides use of an agent which inhibits interaction between CD200 and CD200R in the preparation of a medicament for inhibiting an immune response in a subject, wherein said medicament is adapted to be administered in combination with an immunosuppressive or immunomodulatory drug, and wherein said agent is an antibody, or an antigen-binding fragment thereof, which (a) binds to CD200 and (b) exhibits reduced ADCC or CDC activity or no ADCC or CDC activity.

According to a fifth aspect, the present invention provides use of an agent which inhibits interaction between CD200 and CD200R in the preparation of a medicament for immunosuppression or immunomodulation, wherein said medicament is adapted to be administered in combination with an immunosuppressant or immunomodulatory drug, wherein less of said drug is required to effect said immunosuppression or immunomodulation as compared to administering said drug without said medicament, and wherein said agent is an antibody, or an antigen-binding fragment thereof, which (a) binds to CD200 and (b) exhibits reduced ADCC or CDC activity or no ADCC or CDC

activity.

According to a sixth aspect, the present invention provides use of an agent which inhibits interaction between CD200 and CD200R in the preparation of a medicament for inhibiting rejection of an allograft in an allograft recipient during a rejection episode, wherein said agent is an antibody, or an antigen-binding fragment thereof, which (a) binds to CD200 and (b) exhibits reduced ADCC or CDC activity or no ADCC or CDC activity.

Unless the context clearly requires otherwise, throughout the description and the claims, the words “comprise”, “comprising”, and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in the sense of “including, but not limited to”.

In certain aspects, the present disclosure relates to agents that specifically bind to CD200. CD200-binding agents include but are not limited to polypeptides, small molecules, organometallic compounds, immunomodulatory agents, antibodies, antigen-binding fragments of antibodies, prodrugs, and/or peptidomimetic compounds. The agent may or may not inhibit or reduce the interaction of CD200 with a CD200 receptor (CD200R).

In certain embodiments, an agent that specifically binds CD200 is an anti-CD200 antibody. Antibodies, as referred to herein, include but are not limited to monoclonal and polyclonal antibodies, engineered antibodies (including chimeric, single chain, CDR-grafted, humanized, fully human antibodies, de-immunized antibodies, and artificially selected antibodies), and synthetic or semi-synthetic antibodies. Antibodies of the present disclosure also include other variations and derivatives of an antibody (e.g., an isolated or recombinant antibody, antibody conjugate or antibody derivative) and antibodies that are murine, human, chimeric, humanized, primatized, etc. Antibodies of the present disclosure also include antigen-binding fragments, such as, for example, Fab, Fab', F(ab')₂, F(ab')₃, Fd, Fv, domain _____

antibodies (dAb), other monovalent and divalent fragments, complementarity determining region (CDR) fragments, single-chain antibodies (e.g., scFv, scFab, scFab Δ C), diabodies, triabodies, minibodies, nanobodies, and polypeptides that contain at least a portion of an antibody that is sufficient to confer specific binding to CD200, and fusions and derivatives of the foregoing. In certain aspects, the present disclosure relates to chimeric, humanized, human and de-immunized anti-CD200 antibodies and antigen-binding fragments thereof. In further embodiments, the disclosure relates to antibodies comprising the IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgA, IgD, and/or IgE frameworks.

In particular embodiments, the agent that specifically binds CD200 may be an agent that inhibits the interaction between CD200 and a CD200R. In some embodiments, an agent that inhibits the interaction between CD200 and a CD200R is an anti-CD200 antibody or antigen-binding fragment thereof. In some embodiments, the antibody or antigen-binding fragment exhibits effector function, whereas in other embodiments, the antibody or antigen-binding fragment exhibits reduced or no effector function. In other embodiments, the agent is a soluble CD200R or a nonagonistic soluble CD200.

Accordingly, in certain embodiments, the present disclosure relates to a method of inhibiting an immune response in a subject in need thereof, wherein the method comprises administering to the subject an effective amount of i) an agent which inhibits interaction between CD200 and CD200R and ii) an immunosuppressive or immunomodulatory agent or drug. In certain embodiments, the immune response is a humoral response. In further embodiments, the immune response is an antibody mediated response. The agent may exhibit effector function in some embodiments. Alternatively, the agent may exhibit reduced or no effector function. In particular embodiments, the agent is an anti-CD200 antibody or antigen-binding fragment thereof. In other embodiments, the agent is a soluble CD200R or a nonagonistic soluble CD200. In any of the above embodiments, the immunomodulatory or immunosuppressive drug may target T cells, B cells, both T and B cells, or another immune cell. In particular embodiments, the immunosuppressive drug is cyclosporine A or rapamycin.

In certain embodiments, the present disclosure provides a method of inhibiting

a humoral immune response in a subject in need thereof, wherein the method comprises administering to the subject an effective amount of an anti-CD200 antibody or antigen-binding fragment thereof. In such embodiments, the anti-CD200 antibody or antigen-binding fragment thereof is selected from the group consisting of a human antibody or antigen-binding fragment, a humanized antibody or antigen-binding fragment, a primatized antibody or antigen-binding fragment, a chimeric antibody or antigen-binding fragment, a murine antibody or antigen-binding fragment, and a de-immunized antibody or antigen-binding fragment. The antigen-binding fragment may further be selected from the group consisting of single-chain antibody, Fab, Fab', F(ab')₂, F(ab')₃, Fd, Fv, domain antibody, and any fragment of an anti-CD200 immunoglobulin that confers specific binding to CD200. Any of the aforementioned antibodies or antigen-binding fragments may be conjugated to a molecule, such as a polymer or a polypeptide. The polymer may be, in some embodiments, poly(ethylene) glycol (PEG).

The inhibition of a humoral immune response may include, for example, an inhibition of any one or more of the following responses: a) antigen presentation by APC; b) activation of helper (CD4+) T cells; c) proliferation of helper (CD4+) T-cells; d) differentiation of B cells; e) proliferation of B cells; and f) B-cell production of antibodies. In certain embodiments, the method results in a decrease in the production of B-cell antibodies, wherein the antibodies are selected from IgG, IgM, IgG1, and IgG2a immunoglobulins.

In certain embodiments, the present disclosure provides a method of inhibiting a humoral immune response in a subject in need thereof, wherein the method comprises administering to the subject an effective amount of an anti-CD200 antibody or antigen-binding fragment thereof and further comprises administering to the subject an immunomodulatory or immunosuppressive agent. The immunomodulatory or immunosuppressive agent may target T cells, B cells, both T and B cells, or another immune cell. In certain embodiments, the immunomodulatory or immunosuppressive agent is a calcineurin inhibitor. In further embodiments, the calcineurin inhibitor is selected from tacrolimus and cyclosporine A.

In other embodiments, the immunomodulatory or immunosuppressive agent

administered in combination with an anti-CD200 antibody or fragment thereof is selected from the group consisting of adriamycin, azathiopurine, busulfan, cyclophosphamide, cyclosporine A, Cytoxin, fludarabine, 5-fluorouracil, methotrexate, mycophenolate mofetil, 6-mercaptopurine, a corticosteroid, a nonsteroidal anti-inflammatory, sirolimus (rapamycin), and tacrolimus (FK-506). In alternative embodiments, the immunomodulatory or immunosuppressive agent is an antibody selected from the group consisting of muromonab-CD3, alemtuzumab, basiliximab, daclizumab, rituximab, anti-thymocyte globulin and IVIg. In certain embodiments, the immunomodulatory or immunosuppressive agent is not an inhibitor of the complement pathway (e.g., the agent is not an antibody (such as an anti-C5 antibody) or molecule that inhibits complement activity).

In certain embodiments of the methods described herein, the subject in need of humoral immunosuppression is a mammal, and in further embodiments the subject is a human subject. In particular embodiments, the subject has received or will receive a transplant.

In certain embodiments, the disclosure relates to a method of decreasing the number of circulating B cells in a subject in need thereof, wherein the method comprises administering to the subject (a) an anti-CD200 antibody or antigen-binding fragment thereof and (b) an immunomodulatory or immunosuppressive agent. In additional embodiments, the disclosure relates to a method of decreasing the number of activated CD200-positive T cells in a subject in need thereof, wherein the method comprises administering to the subject (a) an anti-CD200 antibody or antigen-binding fragment thereof and (b) an immunomodulatory or immunosuppressive agent. Further, some embodiments relate to a method of inhibiting B cell activation in a subject in need thereof, wherein the method comprises administering to the subject (a) an anti-CD200 antibody or antigen-binding fragment thereof and (b) an immunomodulatory or immunosuppressive agent. For example, the anti-CD200 antibody or antigen-binding fragment and the agent may be administered in an amount sufficient to decrease the amount of circulating immunoglobulin in the subject. In any of the above embodiments, the subject may be a mammal, such as a primate or human subject. Optionally, the subject has received or will receive a cell, tissue, or organ transplant.

In certain aspects, the present disclosure relates to a method of inhibiting graft rejection in a graft recipient in need thereof, wherein the method comprises administering to the recipient therapeutically effective amounts of (a) an anti-CD200 antibody or antigen-binding fragment thereof and (b) an immunomodulatory or immunosuppressive agent. A therapeutically effective amount may refer to an amount of the combination of a) an anti-CD200 antibody and b) an immunomodulatory or immunosuppressive agent such that the combination is effective in inhibiting graft rejection. In certain embodiments, the anti-CD200 antibody or antigen-binding fragment thereof is selected from the group consisting of a human antibody or antigen-binding fragment thereof, a humanized antibody or antigen-binding fragment thereof, a primatized antibody or antigen-binding fragment thereof, a chimeric antibody or antigen-binding fragment thereof, a murine antibody or antigen-binding fragment thereof, and a de-immunized antibody or antigen-binding fragment thereof. The antigen-binding fragment may further be selected from the group consisting of single-chain antibody, Fab, Fab', F(ab')₂, F(ab')₃, Fd, Fv, domain antibody, and any fragment of an anti-CD200 immunoglobulin that confers specific binding to CD200. Any of the aforementioned antibodies or antigen-binding fragments may be conjugated to a molecule, such as a polymer or a polypeptide. The polymer may be, in some embodiments, poly(ethylene) glycol (PEG).

In certain embodiments of inhibiting graft rejection, the anti-CD200 antibody or antigen-binding fragment thereof and the immunomodulatory or immunosuppressive agent are administered prior to a transplant. In other embodiments, the antibody and agent are administered at the time of transplantation. In other embodiments, the antibody and agent are administered post-transplant. In some embodiments, the graft rejection is an acute humoral rejection of a grafted cell, tissue, or organ. In other embodiments, the graft rejection is a chronic humoral rejection of a grafted cell, tissue, or organ.

In certain embodiments of the present disclosure, the graft recipient is a recipient of a hematopoietic cell or bone marrow transplant, an allogeneic transplant of pancreatic islet cells, or a solid organ transplant selected from the group consisting of a heart transplant, a kidney-pancreas transplant, a kidney transplant, a liver transplant, a lung transplant, and a pancreas transplant. Additional examples of grafts

include but are not limited to allotransplanted cells, tissues, or organs such as vascular tissue, eye, cornea, lens, skin, bone marrow, muscle, connective tissue, gastrointestinal tissue, nervous tissue, bone, stem cells, cartilage, hepatocytes, or hematopoietic cells.

In some embodiments of inhibiting graft rejection, the immunomodulatory or immunosuppressive agent is an agent that targets T cells or B cells or both T cells and B cells. In certain embodiments, the agent does not target the complement pathway and/or does not inhibit complement-mediated immune response. In particular embodiments, the immunomodulatory or immunosuppressive agent is a calcineurin inhibitor. In further embodiments, the calcineurin inhibitor is selected from tacrolimus and cyclosporine A.

In additional embodiments of inhibiting graft rejection, the immunomodulatory or immunosuppressive agent is selected from the group consisting of adriamycin, azathiopurine, busulfan, cyclophosphamide, cyclosporine A, fludarabine, 5-fluorouracil, methotrexate, mycophenolate mofetil, 6-mercaptopurine, a corticosteroid, a nonsteroidal anti-inflammatory, sirolimus (rapamycin), and tacrolimus (FK-506). In alternative embodiments, the immunomodulatory or immunosuppressive agent is an antibody selected from the group consisting of muromonab-CD3, alemtuzumab, basiliximab, daclizumab, rituximab, anti-thymocyte globulin and IVIg.

In certain embodiments, a method comprising administering an anti-CD200 antibody and an immunomodulatory or immunosuppressive agent results in an inhibition of a humoral immune response in the graft recipient. For example, in certain embodiments, the method results in a decrease in the production of anti-donor antibodies. The anti-donor antibodies may be selected from IgG, IgM, IgG1, and IgG2a immunoglobulins. In some embodiments, the graft recipient exhibits or suffers from an acute graft rejection of cell, tissue or organ allo- or xenotransplant. In other embodiments, the graft recipient exhibits or suffers from a chronic graft rejection of cell, tissue or organ allo- or xenotransplant.

In other embodiments, a method comprising administering an anti-CD200 antibody and an immunomodulatory or immunosuppressive agent results in an

inhibition of a cellular immune response in the graft recipient. For example, in certain embodiments, the method results in a decrease in the production of recipient CD4+ and CD8+ T cells in lymphoid tissues. In some embodiments, the graft recipient exhibits or suffers from an acute graft rejection of cell, tissue or organ allo- or xenotransplant. In other embodiments, the graft recipient exhibits or suffers from a chronic graft rejection of cell, tissue or organ allo- or xenotransplant.

In certain aspects, the present disclosure relates to a method of treating or preventing graft rejection in a graft recipient in need thereof, wherein the method comprises administering to the recipient therapeutically effective amounts of (a) an anti-CD200 antibody or antigen-binding fragment thereof and (b) an immunomodulatory or immunosuppressive agent. In further embodiments, the present disclosure relates to a method of promoting or prolonging graft survival in a graft recipient, wherein the method comprises administering to the graft recipient therapeutically effective amounts of (a) an anti-CD200 antibody or antigen-binding fragment thereof and (b) an immunomodulatory or immunosuppressive agent. The anti-CD200 antibody or antigen-binding fragment thereof may be selected from among a human antibody or antigen-binding fragment thereof, a humanized antibody or antigen-binding fragment thereof, a primatized antibody or antigen-binding fragment thereof, a chimeric antibody or antigen-binding fragment thereof, a murine antibody or antigen-binding fragment thereof, and a de-immunized antibody or antigen-binding fragment thereof. The antigen-binding fragment may further be selected from among a single-chain antibody, Fab, Fab', F(ab')₂, F(ab')₃, Fd, Fv, domain antibody, and any fragment of an anti-CD200 immunoglobulin that confers specific binding to CD200.

In further embodiments, a method of prolonging or promoting graft survival of the present disclosure increases graft survival in the recipient by at least about 15%, by at least about 20%, by at least about 25%, by at least about 30%, by at least about 40%, or by at least about 50%, compared to the graft survival observed in a control recipient. A control recipient may be, for example, a graft recipient that does not receive a therapy post-transplant or that receives a monotherapy following transplant.

In certain embodiments, a method of promoting graft survival promotes long-

term graft survival, wherein the long-term graft survival is selected from among: at least about 6 months post transplant, at least about 1 year post transplant; at least about 5 years post transplant; at least about 7.5 years post-transplant; and at least about 10 years post-transplant. In certain embodiments, the therapies described herein promote accommodation of the graft and the graft survives for the remaining life-time of the recipient.

In any of the embodiments of the present disclosure, the graft recipient may be a primate graft recipient, such as a non-human primate graft recipient. In further embodiments, the graft recipient is a human graft recipient.

In any of the embodiments described herein, an anti-CD200 antibody or antigen-binding fragment thereof may be administered systemically to a subject or to a graft recipient. Alternatively, the antibody or antigen-binding fragment thereof may be administered locally to the subject or graft recipient.

In embodiments comprising a combination of an anti-CD200 antibody or antigen-binding fragment thereof and an immunomodulatory or immunosuppressive agent, the anti-CD200 antibody or antigen-binding fragment thereof and immunomodulatory or immunosuppressive agent are administered sequentially. In other embodiments, the antibody or fragment thereof and agent are administered simultaneously.

The application contemplates combinations of any of the foregoing aspects and embodiments. All references and documents cited herein are incorporated in their entirety.

BRIEF DESCRIPTION OF THE FIGURES

Figures 1A-1F depict the amino acid sequences and nucleotide sequences for the heavy and light chains of antibody chC2aB7-hG1 (SEQ ID NOS: 1, 2, 3, 4, 5, and 6). Figure 1C shows SEQ ID NO: 3 (nucleic acid sequence) and SEQ ID NO: 1 (amino acid sequence). SEQ ID NO: 3 as shown in the schematic is contiguous but is depicted with a corresponding nucleotide sequence that includes introns. Figure 1F shows SEQ ID NO: 6 (nucleic acid sequence) and SEQ ID NO: 4 (amino acid sequence). SEQ ID NO:5 (shown in Figure 1E) encodes SEQ ID NO:4 (shown in

Figure 1D).

Figures 2A-2F depict the amino acid sequences and nucleotide sequences for the heavy and light chains of antibody chC2aB7-hG2G4 (SEQ ID NOS: 7, 8, 9, 10, 11, 12, 13, and 14). Figure 2C shows SEQ ID NO: 10 (nucleic acid sequence) and SEQ ID NO: 9 (amino acid sequence). SEQ ID NO: 9 corresponds to amino acids 1-337 of SEQ ID NO: 7. As shown in the schematic, SEQ ID NO: 10 is contiguous but is depicted with a corresponding nucleotide sequence that includes introns. Figure 2F shows SEQ ID NO: 14 (nucleic acid sequence) and SEQ ID NO: 13 (amino acid sequence). SEQ ID NO:12 (shown in Figure 2E) encodes SEQ ID NO:11 (shown in Figure 2D).

Figures 3A-3F depict the amino acid sequences and nucleotide sequences for the heavy and light chains of antibody hB7V3V2-hG1 (SEQ ID NOS: 15, 16, 17, 18, 19, and 20). Figure 3C shows SEQ ID NO: 17 (nucleic acid sequence) and SEQ ID NO: 15 (amino acid sequence). Figure 3F shows SEQ ID NO: 20 (nucleic acid sequence) and SEQ ID NO: 18 (amino acid sequence). SEQ ID NO:19 (shown in Figure 3E) encodes SEQ ID NO:18 (shown in Figure 3D).

Figures 4A-4F depict the amino acid sequences and nucleotide sequences for the heavy and light chains of antibody hB7V3V2-hG2G4 (SEQ ID NOS: 21, 22, 23, 24, 25, and 26). Figure 4C shows SEQ ID NO: 23 (nucleic acid sequence) and SEQ ID NO: 21 (amino acid sequence). SEQ ID NO: 23 as shown in the schematic is contiguous but is depicted with a corresponding nucleotide sequence that includes introns. Figure 4F shows SEQ ID NO: 26 (nucleic acid sequence) and SEQ ID NO: 24 (amino acid sequence). SEQ ID NO:25 (shown in Figure 4E) encodes SEQ ID NO:24 (shown in Figure 4D).

Figure 5 shows flow cytometric analysis of CD200 expression on activated T-cells. CD3+ human cells were activated with mOKT3, harvested, washed and subjected to staining with the indicated fluorochrome-conjugated antibodies specific for human CD25, CD200, CD5, CD4 and CD8. Cells were washed and analyzed for immunofluorescence on a FACSCalibur flow cytometer using CellQuest software. Activation of human T cells results in a dramatic upregulation of CD200 expression.

Figure 6 demonstrates the effects of anti-CD200 antibodies on ADCC of activated T-cells. CD3+ human T cells were stimulated with 10 µg/mL immobilized

(plate-coated) mOKT3 for 72 hrs. Activated T cells were then chromated for use as targets and incubated with purified autologous CD56+ (NK) cells as effector cells. Cells were coincubated for 4 hours at 37°C at 25:1 (A) or 10:1 (B) effector:target cell ratios in the presence or absence of a humanized anti-CD200 antibody capable of mediating effector function (V3V2-G1) or engineered to lack effector function (V3V2-G2G4). Data are represented as percent specific lysis. The anti-CD200 antibody with effector function efficiently mediated ADCC of the activated T-cell targets, whereas the anti-CD200 antibody with no effector function failed to mediate ADCC.

Figures 7A-B demonstrate that an anti-CD200 antibody administered in combination with an inhibitor of T cells (cyclosporine A) leads to a significant reduction in antibody production, or an inhibition of a humoral immune response, in a murine heart allograft model. Figure 7A provides the relative levels of circulating anti-donor IgG antibodies in heart allograft recipients following various immunomodulatory treatments. Figure 7B provides the relative levels of circulating anti-donor IgM antibodies in heart allograft recipients following various immunomodulatory treatments. MFI is mean fluorescent intensity.

Figure 8 indicates the levels of splenic CD4+ and CD8+ T cells in mouse heart allograft recipients following various immunomodulatory treatments, including an anti-CD200 antibody and cyclosporine A. Splenic cells from graft recipients were analyzed by flow cytometry.

Figures 9A-C provide the levels of CD3CD200; CD3CD200R, CD19CD200, CD19CD200R, CD11cCD200, and CD11cCD200R positive cells in mouse heart allograft recipients following treatment with an anti-CD200 antibody and cyclosporine A.

Figure 10 shows the sequences of the heavy chains of OX90NE (SEQ ID NO:27) and OX90mG2a (SEQ ID NO:28). The four amino acid differences between the two molecules are highlighted in bold (amino acid residues 236, 319, 321 and 323). The variable portion of each encompasses amino acid residues 1-118. The constant region for each comprises amino acid residues 119-448.

Figure 11 shows that the OX90 antibodies are blocking antibodies in that they block the binding of CD200 to the CD200R1 receptor.

DETAILED DESCRIPTION

I. OVERVIEW

A. Rejection of Transplants or Grafts

Hyperacute rejection occurs within minutes to hours after transplant and is due to preformed antibodies to the transplanted tissue antigens. It is characterized by hemorrhage and thrombotic occlusion of the graft vasculature. The binding of antibody to endothelium activates complement, and antibody and complement induce a number of changes in the graft endothelium that promote intravascular thrombosis and lead to vascular occlusion, resulting in irreversible ischemic damage of the grafted organ (Abbas et al., 2000 *Cellular and Molecular Immunology* (4th edition), p. 363-383 (W.B. Saunders Company, New York)). Hyperacute rejection is often mediated by preexisting IgM alloantibodies, e.g., antibodies directed against the ABO blood group antigens expressed on red blood cells. This type of rejection, mediated by natural antibodies, is the main reason for rejection of xenotransplants. Hyperacute rejection due to natural IgM antibodies is no longer a major problem with allografts because allografts are usually selected to match the donor and recipient ABO type. Hyperacute rejection of an ABO matched allograft may still occur and is usually mediated by IgG antibodies directed against protein alloantigens, such as foreign MHC molecules, or against less well defined alloantigens expressed on vascular endothelial cells. Such IgG antibodies may arise as a result of prior exposure to alloantigens through blood transfusion, prior transplantation, or multiple pregnancies, for example.

Acute rejection is a process of vascular and parenchymal injury mediated by T cells, macrophages, and antibodies that usually begins after the first week of transplantation (Abbas et al., *supra*). T lymphocytes play a central role in acute rejection by responding to alloantigens, including MHC molecules, present on vascular endothelial and parenchymal cells. The activated T cells cause direct lysis of graft cells or produce cytokines that recruit and activate inflammatory cells, which cause necrosis. Both CD4⁺ and CD8⁺ T cells may contribute to acute rejection. The destruction of allogeneic cells in a graft is highly specific and is a hallmark of CD8⁺

cytotoxic T lymphocyte killing. CD4⁺ T cells may be important in mediating acute graft rejection by secreting cytokines and inducing delayed-type hypersensitivity-like reactions in grafts; some evidence indicates that CD4⁺ T cells are sufficient to mediate acute rejection (Abbas et al., *supra*). Antibodies can also mediate acute rejection after a graft recipient mounts a humoral immune response to vessel wall antigens when the antibodies that are produced bind to the vessel wall and activate complement (Abbas et al., *supra*).

Chronic rejection is characterized by fibrosis with loss of normal organ structures occurring over a prolonged period. The pathogenesis of chronic rejection is less well understood than the pathogenesis of acute rejection. Graft arterial occlusion may occur as a result of the proliferation of intimal smooth muscle cells (Abbas et al., *supra*). This process is called accelerated or graft arteriosclerosis and can develop in any vascularized organ transplant within 6 months to a year after transplantation.

Allografts are rejected in part by the activation of T cells. The transplant recipient mounts a rejection response following CD4⁺ T cell recognition of foreign antigens in the allograft. These antigens are encoded by the major histocompatibility complex (MHC) of which there are both Class I and Class II MHC molecules. In humans the class I MHC molecules are HLA-A, HLA-B, and HLA-C. The class II MHC molecules in humans are HLA-DR, HLA-DQ and HLA-DP. In mice the class I MHC molecules are H-2K, H-2D and H-2L and the class II MHC molecules are I-A and I-E. When CD4⁺ T cells bind processed or intact foreign MHC antigens they are activated and undergo clonal proliferation. The activated T cells secrete cytokines which aid in activating monocytes/macrophages, B cells and cytotoxic CD8⁺ T cells. The activated monocytes/macrophages release agents which result in tissue damage, the B cells produce alloantibodies which lead to complement-mediated graft destruction, and the CD8⁺ T cells kill graft cells in an antigen-specific manner through induction of apoptosis and cell lysis.

The importance of humoral immunity in graft rejection was initially thought to be limited to hyperacute rejection, in which the graft recipient possesses anti-donor HLA antibodies prior to transplantation, resulting in rapid destruction of the graft in the absence of an effective therapeutic regimen of antibody suppression. Recently, it

has become evident that humoral immunity is also an important factor mediating both acute and chronic rejection. For example, clinical observations demonstrated that graft survival in patients capable of developing class I or class II anti-HLA alloantibodies (also referred to as "anti-MHC alloantibodies") was reduced compared to graft survival in patients that could not develop such antibodies. Clinical and experimental data also indicate that other donor-specific alloantibodies and autoantibodies are critical mediators of rejection. For a review of the evidence supporting a role for donor-specific antibodies in allograft rejection, see Rifle et al., *Transplantation*, 2005 79:S14-S18.

B. Immunosuppressive Agents

For a transplant to be successful, several modes of rejection must be overcome. Therefore multiple approaches are utilized in preventing or inhibiting rejection. Inhibiting graft rejection may require administration of immunosuppressants, often of several types, to prevent or inhibit the various modes of attack—e.g., inhibition of T-cell attack, inhibition of antibody responses, and inhibition of cytokine and complement effects. Prescreening of donors to match them with recipients is also a major factor in preventing rejection, especially in preventing hyperacute rejection. Immunoabsorption of anti-HLA antibodies prior to grafting may reduce hyperacute rejection. Prior to transplantation, the recipient or host may be administered anti-T cell reagents, e.g., the monoclonal antibody OKT3, Anti-Thymocyte Globulin (ATG), cyclosporine A, or tacrolimus (FK 506). Additionally, glucocorticoids and/or azathioprine (or other purine analogs) may be administered to the host prior to transplant. Drugs used to aid in preventing or inhibiting transplant rejection include, but are not limited to, ATG or ALG, OKT3, daclizumab, basiliximab, corticosteroids, 15-deoxyspergualin, LF15-0195, cyclosporins, tacrolimus, purine analogs such as azathioprine, methotrexate, mycophenolate mofetil, 6-mercaptopurine, bredinin, brequinar, leflunamide, cyclophosphamide, sirolimus, anti-CD4 monoclonal antibodies, CTLA4-Ig, rituxan, anti-CD154 monoclonal antibodies, anti-LFA1 monoclonal antibodies, anti-LFA-3 monoclonal antibodies, anti-CD2 monoclonal antibodies, and anti-CD45.

The numerous drugs utilized to delay graft rejection (i.e., to prolong graft

survival) work in a variety of ways. See Stepkowski (2000). *Exp. Rev. Mol. Med.* 21 June, world wide web at expertreviews.org/00001769h.htm for a review of the mechanisms of action of several immunosuppressive drugs.

Cyclosporine A is one of the most widely used immunosuppressive drugs for inhibiting graft rejection. It is an inhibitor of interleukin-2 or IL-2 (it prevents mRNA transcription of interleukin-2). More directly, cyclosporine inhibits calcineurin activation that normally occurs upon T cell receptor stimulation. Calcineurin dephosphorylates NFAT (nuclear factor of activated T cells), thereby enabling NFAT to enter the nucleus and bind to interleukin-2 promoter. By blocking this process, cyclosporine A inhibits the activation of the CD4⁺ T cells and the resulting cascade of events which would otherwise occur. Tacrolimus is another immunosuppressant that acts by inhibiting the production of interleukin-2 via calcineurin inhibition.

Rapamycin (Sirolimus), SDZ RAD, and interleukin-2 receptor blockers are drugs that inhibit the action of interleukin-2 and therefore prevent the cascade of events described above.

Inhibitors of purine or pyrimidine biosynthesis are also used to inhibit graft rejection. These inhibitors prevent DNA synthesis and thereby inhibit cell division including T cell proliferation. The result is the inhibition of T cell activity by preventing the formation of new T cells. Inhibitors of purine synthesis include azathioprine, methotrexate, mycophenolate mofetil (MMF) and mizoribine (bredinin). Inhibitors of pyrimidine synthesis include brequinar sodium and leflunomide. Cyclophosphamide is an inhibitor of both purine and pyrimidine synthesis.

Yet another method for inhibiting T cell activation is to treat the recipient with antibodies to T cells. OKT3 is a murine monoclonal antibody against CD3 which is part of the T cell receptor. This antibody initially activates T cells through the T cell receptor, then induces apoptosis of the activated T cell.

Numerous other drugs and methods for delaying allograft rejection are known to and used by persons of skill in the art. One approach is to deplete T cells, e.g., by irradiation. Depletion of T cells has often been used in bone marrow transplants, especially if there is a partial mismatch of major HLA. Administration to the recipient of an inhibitor (blocker) of the CD40 ligand-CD40 interaction and/or a

blocker of the CD28-B7 interaction has also been used (U.S. Patent 6,280,957). Published PCT patent application WO 01/37860 discloses the administration of an anti-CD3 monoclonal antibody and IL-5 to inhibit the Th1 immune response. Published PCT patent application WO 00/27421 teaches a method for prophylaxis or treatment of corneal transplant rejection by administering a tumor necrosis factor- α antagonist. Glotz et al. (2002 *Am. J. Transplant.* 2:758-760) show that administration of intravenous immunoglobulins (IVIg) can induce a profound and sustained decrease in the titers of anti-HLA antibodies thereby allowing survival of an HLA-mismatched organ. Similar protocols have included plasma exchanges (Taube et al., 1984 *Lancet* 1:824-828) or immunoabsorption techniques coupled to immunosuppressive agents (Hiesse et al., 1992 *Nephrol. Dial. Transplant.* 7:944-951) or a combination of these methods (Montgomery et al., 2000 *Transplantation* 70:887-895). Changelian et al. (2003 *Science* 302:875-878) teach a model in which immunosuppression is caused by an oral inhibitor of Janus kinase 3 (JAK3), which is an enzyme necessary for the proper signaling of cytokine receptors which use the common gamma chain (γc) (Interleukins-2, -4, -7, -9, -15, -21), the result being an inhibition of T cell activation. Antisense nucleic acids against ICAM-1 have been used alone or in combination with a monoclonal antibody specific for leukocyte-function associated antigen 1 (LFA-1) in a study of heart allograft transplantation (Stepkowski, *supra*). Similarly, an anti-ICAM-1 antibody has been used in combination with anti-LFA-1 antibody to treat heart allografts (Stepkowski, *supra*). Antisense oligonucleotides have additionally been used in conjunction with cyclosporine in rat heart or kidney allograft models, resulting in a synergistic effect to prolong the survival of the grafts (Stepkowski, *supra*). Chronic transplant rejection has been treated by administering an antagonist of TGF- β , which is a cytokine involved in differentiation, proliferation, and apoptosis (U.S. Patent Application Publication US 2003/0180301).

C. CD200 and Immunosuppression

Another mechanism that has been thought to be involved in suppressing the immune response involves the molecule CD200. CD200 is a highly conserved type I transmembrane glycoprotein expressed on various cell types including cells of the immune system (e.g., T-cells, B-cells, and dendritic cells (Barclay et al., 2002 *TRENDS Immunol.* 23:285-290)) as well as certain cancer cells. The protein interacts

with its receptor CD200R on myeloid cells and sub-populations of T cells (Wright et al. 2003 *J. Immunol.* 171: 3034-3046 and Wright et al., 2000 *Immunity* 13:233-242); it has been thought that the CD200:CD200R interaction delivers an immunomodulatory signal to cells and induces immunosuppression including apoptosis-associated immune tolerance (Rosenblum et al. 2004 *Blood* 103: 2691-2698).

Previous studies, especially numerous articles by Gorczynski et al., have indicated that CD200 is immunosuppressive. For example, Gorczynski et al. (*Clin. Immunol.* 104:256-264 (2002)) teach that in a mouse collagen-induced arthritis (CIA) model, treatment with soluble CD200 (CD200Fc) ameliorates CIA. In the transplant setting, Gorczynski et al. (*Eur. J. Immunol.* 31: 2331-2337 (2001)) report that soluble CD200 protein promotes allograft survival while anti-CD200 antibodies prevent immunosuppression and result in shortened times of allograft survival.

In contrast to previous reports, the present disclosure demonstrates that administration of an anti-CD200 antibody promotes graft survival. While not wishing to be bound by any particular mechanism(s) of action, prolonged survival of a graft may be due to the killing or inactivation of T-cells and/or the inhibition of B-cell activity (e.g., inhibition of a humoral response against the graft). For example, CD200 is highly expressed on activated T and B cells, compared with lower levels of expression on resting cells. Accordingly, administration of an anti-CD200 antibody could result in activated T cells and B cells being coated with antibody, rendering the cells susceptible to antibody-mediated cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and/or other effector functions such as apoptosis. One possible result of antibody administration could be, therefore, killing of activated immune cells and a suppression of the immune response. However, as described below, this effect is seen not only with antibodies which have effector function but also with antibodies lacking effector function. Therefore, it appears that if the killing of B and/or T cells is involved, effector function is only part of the story. As shown below, inhibiting the interaction of CD200 with the CD200 receptor (CD200R), whether using an antibody with effector function or without effector function, can suppress the immune response and promote graft survival as well as be used in ameliorating autoimmune disease. Again, without wishing to be bound by any

particular mechanism of action, the inhibition of binding of CD200 to CD200R seems to be the important first step.

Accordingly, anti-CD200 antibody administration may prolong graft survival via one or more of the following mechanisms: (i) inhibition of antibody production (e.g., via a reduction in the number of B cells, such as by killing of B cells); (ii) alteration of cytokine production (e.g., production of TNF- α and IL-12) by, for example, a reduction in the number of T cells (such as by T cell killing, for example); (iii) induction of an intravenous immunoglobulin (IVIg) effect (e.g., soluble CD200 shed from the cell surface may bind to the anti-CD200 antibody to form a complex); (iv) interference with antigen presentation, resulting in subsequent anergy of immune cells; (v) induction of immune regulation; and/or (vi) inhibition or blocking of the activity of other presently unknown CD200 interactions that are immunostimulatory. As possible scenarios for this latter mechanism, different CD200 receptors exist (e.g., five receptors are known in mouse and two receptors are known in human), and these different receptors use different signaling mechanisms (e.g., extended cytoplasmic domains versus adapter proteins such as DAP12) (Wright et al. *J. Immunol.*, 2003, 171: 3034-3046). Accordingly, it is possible that the different signaling pathways mediated by the different CD200Rs could have opposing effects on the immune system. Additionally or alternatively, while it is thought that the immunosuppressive activity of CD200 is mediated via the CD200:CD200R interaction, an anti-CD200 receptor antibody may crosslink the CD200 receptor, thereby activating the receptor and inducing immune suppression.

II. CD200-BINDING AGENTS

The present disclosure relates to compositions and methods for inhibiting or preventing graft rejection and prolonging graft survival. In certain aspects, the present disclosure relates to CD200-binding agents. As used herein, a CD200-binding agent includes any agent that is capable of specifically binding CD200. Examples of CD200-binding agents include but are not limited to polypeptides, antibodies, small molecules, and peptidomimetics. In certain embodiments, the CD200-binding agent disrupts the interaction of CD200 and CD200R. In other embodiments, the CD200-

binding agents are capable of targeting CD200-expressing cells for depletion or elimination.

In certain aspects, the CD200-binding agents are polypeptides. Polypeptides utilized in the present disclosure can be constructed using different techniques that are known to persons skilled in the art. In one embodiment, the polypeptides are obtained by chemical synthesis. In other embodiments, the polypeptides are antibodies constructed from a fragment or several fragments of one or more antibodies. In further embodiments, the polypeptide is an anti-CD200 antibody as described herein.

Thus in certain embodiments, the CD200-binding agents are anti-CD200 antibodies. As used herein, the term "antibodies" refers to complete antibodies or antibody fragments capable of binding to CD200. Included are monoclonal and polyclonal antibodies, engineered antibodies (including chimeric, single chain, CDR-grafted, humanized, fully human antibodies, and artificially selected antibodies), and synthetic or semi-synthetic antibodies produced using phage display or alternative techniques, and other variations and derivatives of an antibody (e.g., an isolated, recombinant or synthetic antibody, antibody conjugate or antibody derivative, and an antigen-binding fragment). Also included are antibodies that are murine, chimeric, human, humanized, primatized, etc. Antigen-binding fragments include, for example, Fab, Fab', F(ab')₂, F(ab')₃, Fd, Fv, domain antibodies (dAb), other monovalent and divalent fragments, complementarity determining region (CDR) fragments, single-chain antibodies (e.g., scFv, scFab, scFabΔC), diabodies, triabodies, minibodies, nanobodies, and polypeptides that contain at least a portion of an antibody that is sufficient to confer specific binding to CD200; and fusions and derivatives of the foregoing. An Fd fragment is an antibody fragment that consists of the V_H and C_{H1} domains; an Fv fragment consists of the V_L and V_H domains of a single arm of an antibody; an scFv fragment is a single chain antibody comprising a heavy chain variable region (V_H) and a light chain variable region (V_L) joined by a peptide linker; an scFab fragment is a single chain antibody comprising a fragment difficult (Fd) joined to a light chain by a peptide linker; a scFabΔC fragment is a scFab variant without cysteines (see, e.g., Hust et al., *BMC Biotech* 7: 14 (2007)), and a dAb fragment (single domain antibody) comprises a single variable domain (e.g., a V_H or a V_L domain) (Ward et al., *Nature* 341:544-546 (1989)). See, e.g., Holliger and

Hudson, *Nature Biotechnology* 23: 1126-1136 (2005). Small fragments, such as Fv and scFv, possess advantageous properties for diagnostic and therapeutic applications on account of their small size and consequent superior tissue distribution. To improve in vivo stability and the in vivo half-life of small fragments, the fragments may be conjugated (directly or indirectly) to a molecule such as poly(ethylene) glycol, for example.

The present disclosure also relates to antibodies engineered or produced in ways to contain variant or altered constant or Fc regions with either increased or decreased ability to bind one or more effector cells; such variant antibodies include but are not limited to antibodies in which the constant or Fc region contains altered glycosylation patterns. Antibodies with engineered or variant constant or Fc regions can be useful in modulating effector functions, such as, for example, ADCC and CDC. Such antibodies with engineered or variant constant or Fc regions may be useful in instances where CD200 is expressed in normal tissue, for example; variant anti-CD200 antibodies without effector function in these instances may elicit the desired therapeutic response while not damaging normal tissue.

The disclosure also relates to anti-CD200 antibodies comprising heavy and light chains as provided herein, including heavy and light chains that are homologous or similar to the heavy and/or light chains provided herein. "Homology" or "identity" or "similarity" refers to sequence similarity between two peptides or between two nucleic acid molecules. Homology and identity can each be determined by comparing a position in each sequence which may be aligned for purposes of comparison. When an equivalent position in the compared sequences is occupied by the same base or amino acid, then the molecules are identical at that position; when the equivalent site is occupied by the same or a similar amino acid residue (e.g., similar in steric and/or electronic nature), then the molecules can be referred to as homologous (similar) at that position. Expression as a percentage of homology/similarity or identity refers to a function of the number of identical or similar amino acids at positions shared by the compared sequences. The term "homology" describes a mathematically based comparison of sequence similarities which is used to identify genes or proteins with similar functions or motifs. As used herein, "identity" means the percentage of identical nucleotide or amino acid residues at corresponding positions in two or more

sequences when the sequences are aligned to maximize sequence matching, i.e., taking into account gaps and insertions. Thus methods to determine identity are designed to give the largest match between the sequences tested (see Computational Molecular Biology, Lesk, A. M., ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D. W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, Griffin, A. M., and Griffin, H. G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., Stockton Press, New York, 1991; and Carillo, H., and Lipman, D., SIAM J. Applied Math., 48: 1073 (1988), Devereux, J., et al., Nucleic Acids Research 12(1): 387 (1984), BLASTP, BLASTN, FASTA (Altschul, S. F. et al., J. Mol. Biol. 215: 403-410 (1990) and Altschul et al. Nucleic Acids Res. 25: 3389-3402 (1997)) and BLAST X (BLAST Manual, Altschul, S., et al., NCBI NLM NIH Bethesda, Md. 20894; Altschul, S., et al., J. Mol. Biol. 215: 403-410 (1990)). A sequence which is "unrelated" or "non-homologous" shares less than 40% identity, though preferably less than 25% identity with a sequence of the present disclosure. In comparing two sequences, the absence of residues (amino acids or nucleic acids) or presence of extra residues also decreases the identity and homology/similarity.

Accordingly, the disclosure relates to antibodies as described herein without the leader sequences. Thus antibodies of the disclosure may comprise heavy and light chains in which the leader sequence is either absent or replaced by a different leader sequence. If host cells are used to produce antibodies of the present disclosure, appropriate leader sequences may therefore be selected according to the particular host cell used.

Antibodies may be produced by methods well known in the art. For example, monoclonal anti-CD200 antibodies may be generated using CD200 positive cells, CD200 polypeptide, or a fragment of CD200 polypeptide as an immunogen, thus raising an immune response in animals from which antibody-producing cells and in turn monoclonal antibodies may be isolated. The sequence of such antibodies may be determined and the antibodies or variants thereof produced by recombinant techniques. Recombinant techniques may be used to produce chimeric, CDR-grafted,

humanized and fully human antibodies based on the sequence of the monoclonal antibodies as well as polypeptides capable of binding to CD200.

Moreover, antibodies derived from recombinant libraries ("phage antibodies") may be selected using CD200-positive cells, or polypeptides derived therefrom, as bait to isolate the antibodies or polypeptides on the basis of target specificity. The production and isolation of non-human and chimeric anti-CD200 antibodies are well within the purview of the skilled artisan.

Recombinant DNA technology is used to improve the antibodies produced in non-human cells. Thus, chimeric antibodies may be constructed in order to decrease the immunogenicity thereof in diagnostic or therapeutic applications. Moreover, immunogenicity may be minimized by humanizing the antibodies by CDR grafting and, optionally, framework modification. See, U.S. Patent No. 5,225,539, the contents of which are incorporated herein by reference.

Antibodies may be obtained from animal serum or, in the case of monoclonal antibodies or fragments thereof, produced in cell culture. Recombinant DNA technology may be used to produce the antibodies according to established procedure, including procedures in bacterial or preferably mammalian cell culture. The selected cell culture system preferably secretes the antibody product.

In another embodiment, a process for the production of an antibody disclosed herein includes culturing a host, e.g. *E. coli* or a mammalian cell, which has been transformed with a hybrid vector. The vector includes one or more expression cassettes containing a promoter operably linked to a first DNA sequence encoding a signal peptide linked in the proper reading frame to a second DNA sequence encoding the antibody protein. The antibody protein is then collected and isolated. Optionally, the expression cassette may include a promoter operably linked to polycistronic, for example bicistronic, DNA sequences encoding antibody proteins each individually operably linked to a signal peptide in the proper reading frame.

Multiplication of hybridoma cells or mammalian host cells in vitro is carried out in suitable culture media, which include the customary standard culture media (such as, for example Dulbecco's Modified Eagle Medium (DMEM) or RPMI 1640 medium), optionally replenished by a mammalian serum (e.g. fetal calf serum), or trace elements and growth sustaining supplements (e.g. feeder cells such as normal

mouse peritoneal exudate cells, spleen cells, bone marrow macrophages, 2-aminoethanol, insulin, transferrin, low density lipoprotein, oleic acid, or the like). Multiplication of host cells which are bacterial cells or yeast cells is likewise carried out in suitable culture media known in the art. For example, for bacteria suitable culture media include medium LE, NZCYM, NZYM, NZM, Terrific Broth, SOB, SOC, 2 x YT, or M9 Minimal Medium. For yeast, suitable culture media include medium YPD, YEPD, Minimal Medium, or Complete Minimal Dropout Medium.

In vitro production provides relatively pure antibody preparations and allows scale-up production to give large amounts of the desired antibodies. Techniques for bacterial cell, yeast, plant, or mammalian cell cultivation are known in the art and include homogeneous suspension culture (e.g. in an airlift reactor or in a continuous stirrer reactor), and immobilized or entrapped cell culture (e.g. in hollow fibers, microcapsules, on agarose microbeads or ceramic cartridges).

Large quantities of the desired antibodies can also be obtained by multiplying mammalian cells *in vivo*. For this purpose, hybridoma cells producing the desired antibodies are injected into histocompatible mammals to cause growth of antibody-producing tumors. Optionally, the animals are primed with a hydrocarbon, especially mineral oils such as pristane (tetramethyl-pentadecane), prior to the injection. After one to three weeks, the antibodies are isolated from the body fluids of those mammals. For example, hybridoma cells obtained by fusion of suitable myeloma cells with antibody-producing spleen cells from Balb/c mice, or transfected cells derived from hybridoma cell line Sp2/0 that produce the desired antibodies are injected intraperitoneally into Balb/c mice optionally pre-treated with pristane. After one to two weeks, ascitic fluid is taken from the animals.

The foregoing, and other, techniques are discussed in, for example, Kohler and Milstein, (1975) *Nature* 256:495-497; U.S. Patent No. 4,376,110; Harlow and Lane, *Antibodies: a Laboratory Manual*, (1988) Cold Spring Harbor, the disclosures of which are all incorporated herein by reference. Techniques for the preparation of recombinant antibody molecules are described in the above references and also in, for example WO97/08320; U.S. Patent No. 5,427,908; U.S. Patent No. 5,508,717; Smith, 1985, *Science*, Vol. 225, pp 1315-1317; Parmley and Smith, 1988, *Gene* 73, pp 305-318; De La Cruz et al., 1988, *Journal of Biological Chemistry*, 263 pp 4318-4322;

U.S. Patent No. 5,403,484; U.S. Patent No. 5,223,409; WO88/06630; WO92/15679; U.S. Patent No. 5,780,279; U.S. Patent No. 5,571,698; U.S. Patent No. 6,040,136; Davis et al., 1999, *Cancer Metastasis Rev.*, 18(4):421-5; Taylor, et al., *Nucleic Acids Research* 20 (1992): 6287-6295; Tomizuka et al., *Proc. Natl. Academy of Sciences USA* 97(2) (2000): 722-727. The contents of all these references are incorporated herein by reference.

The cell culture supernatants are screened for the desired antibodies, preferentially by immunofluorescent staining of CD200-positive cells, by immunoblotting, by an enzyme immunoassay, e.g. a sandwich assay or a dot-assay, or a radioimmunoassay.

For isolation of the antibodies, the immunoglobulins in the culture supernatants or in the ascitic fluid may be concentrated, e.g. by precipitation with ammonium sulfate, dialysis against hygroscopic material such as polyethylene glycol, filtration through selective membranes, or the like. If necessary and/or desired, the antibodies are purified by the customary chromatography methods, for example gel filtration, ion-exchange chromatography, chromatography over DEAE-cellulose and/or (immuno-) affinity chromatography, e.g. affinity chromatography with one or more surface polypeptides derived from a CD200-positive cell line, or with Protein-A or -G.

Another embodiment provides a process for the preparation of a bacterial cell line secreting antibodies directed against CD200 in a suitable mammal. For example a rabbit is immunized with pooled samples from CD200-positive tissue or cells or CD200 polypeptide or fragments thereof. A phage display library produced from the immunized rabbit is constructed and panned for the desired antibodies in accordance with methods well known in the art (such as, for example, the methods disclosed in the various references incorporated herein by reference).

Hybridoma cells secreting the monoclonal antibodies are also disclosed. The preferred hybridoma cells are genetically stable, secrete monoclonal antibodies described herein of the desired specificity, and can be expanded from deep-frozen cultures by thawing and propagation in vitro or as ascites in vivo.

In another embodiment, a process is provided for the preparation of a hybridoma cell line secreting monoclonal antibodies against CD200. In that process,

a suitable mammal, for example a Balb/c mouse, is immunized with one or more polypeptides or antigenic fragments of CD200 or with one or more polypeptides or antigenic fragments derived from a CD200-positive cell, the CD200-positive cell itself, or an antigenic carrier containing a purified polypeptide as described. Antibody-producing cells of the immunized mammal are grown briefly in culture or fused with cells of a suitable myeloma cell line. The hybrid cells obtained in the fusion are cloned, and cell clones secreting the desired antibodies are selected. For example, spleen cells of Balb/c mice immunized with a CD200-positive Chronic Lymphocytic Leukemia (CLL) cell line are fused with cells of the myeloma cell line PAI or the myeloma cell line Sp2/0-Ag 14. The obtained hybrid cells are then screened for secretion of the desired antibodies and positive hybridoma cells are cloned.

Preferred is a process for the preparation of a hybridoma cell line, characterized in that Balb/c mice are immunized by injecting subcutaneously and/or intraperitoneally between 10^6 and 10^7 cells of a CD200-positive cell line several times, e.g. four to six times, over several months, e.g. between two and four months. Spleen cells from the immunized mice are taken two to four days after the last injection and fused with cells of the myeloma cell line PAI in the presence of a fusion promoter, preferably polyethylene glycol. Preferably, the myeloma cells are fused with a three- to twenty-fold excess of spleen cells from the immunized mice in a solution containing about 30% to about 50% polyethylene glycol of a molecular weight around 4000. After the fusion, the cells are expanded in suitable culture media as described hereinbefore, supplemented with a selection medium, for example HAT medium, at regular intervals in order to prevent normal myeloma cells from overgrowing the desired hybridoma cells.

The antibodies and fragments thereof can be "chimeric". Chimeric antibodies and antigen-binding fragments thereof comprise portions from two or more different species (e.g., mouse and human). Chimeric antibodies can be produced with mouse variable regions of desired specificity spliced into human constant domain gene segments (for example, U.S. patent No. 4,816,567). In this manner, non-human antibodies can be modified to make them more suitable for human clinical application.

The monoclonal antibodies of the present disclosure also include "humanized" forms of the non-human (i.e., mouse) antibodies. Humanized or CDR-grafted mAbs are particularly useful as therapeutic agents for humans because they are not cleared from the circulation as rapidly as mouse antibodies and do not typically provoke an adverse immune reaction. Generally, a humanized antibody has one or more amino acid residues introduced into it from a non-human source. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Methods of preparing humanized antibodies are generally well known in the art. For example, humanization can be essentially performed following the method of Winter and co-workers (Jones et al., *Nature* 321:522-525 (1986); Riechmann et al., *Nature*, 332:323-327 (1988); Verhoeyen et al., *Science*, 239: 1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Also see Staelens et al. 2006 *Mol Immunol* 43: 1243-1257. In particular embodiments, humanized forms of non-human (e.g., mouse) antibodies are human antibodies (recipient antibody) in which hypervariable (CDR) region residues of the recipient antibody are replaced by hypervariable region residues from a non-human species (donor antibody) such as a mouse, rat, rabbit, or non-human primate having the desired specificity, affinity, and binding capacity. In some instances, framework region residues of the human immunoglobulin are also replaced by corresponding non-human residues (so called "back mutations"). In addition, phage display libraries can be used to vary amino acids at chosen positions within the antibody sequence. The properties of a humanized antibody are also affected by the choice of the human framework. Furthermore, humanized and chimerized antibodies can be modified to comprise residues that are not found in the recipient antibody or in the donor antibody in order to further improve antibody properties, such as, for example, affinity or effector function.

Fully human antibodies are also provided in the disclosure. The term "human antibody" includes antibodies having variable and constant regions (if present) derived from human germline immunoglobulin sequences. Human antibodies can include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis *in vitro*

or by somatic mutation *in vivo*). However, the term "human antibody" does not include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences (i.e., humanized antibodies). Fully human or human antibodies may be derived from transgenic mice carrying human antibody genes (carrying the variable (V), diversity (D), joining (J), and constant (C) exons) or from human cells. For example, it is now possible to produce transgenic animals (e.g., mice) that are capable, upon immunization, of producing a full repertoire of human antibodies in the absence of endogenous immunoglobulin production (see, e.g., Jakobovits et al., *Proc. Natl. Acad. Sci. USA*, 90:2551 (1993); Jakobovits et al., *Nature*, 362:255-258 (1993); Bruggemann et al., *Year in Immuno.*, 7:33 (1993); and Duchosal et al. *Nature* 355:258 (1992). Transgenic mice strains can be engineered to contain gene sequences from unarranged human immunoglobulin genes. The human sequences may code for both the heavy and light chains of human antibodies and would function correctly in the mice, undergoing rearrangement to provide a wide antibody repertoire similar to that in humans. The transgenic mice can be immunized with the target protein (e.g., CD200, fragments thereof, or cells expressing CD200) to create a diverse array of specific antibodies and their encoding RNA. Nucleic acids encoding the antibody chain components of such antibodies may then be cloned from the animal into a display vector. Typically, separate populations of nucleic acids encoding heavy and light chain sequences are cloned, and the separate populations then recombined on insertion into the vector, such that any given copy of the vector receives a random combination of a heavy and a light chain. The vector is designed to express antibody chains so that they can be assembled and displayed on the outer surface of a display package containing the vector. For example, antibody chains can be expressed as fusion proteins with a phage coat protein from the outer surface of the phage. Thereafter, display packages can be screened for display of antibodies binding to a target.

In addition, human antibodies can be derived from phage-display libraries (Hoogenboom et al., *J. Mol. Biol.*, 227:381 (1992); Marks et al., *J. Mol. Biol.*, 222:581-597 (1991); Vaughan et al. *Nature Biotech* 14:309 (1996)). Synthetic phage libraries can be created which use randomized combinations of synthetic human

antibody V-regions. By selection on antigen fully human antibodies can be made in which the V-regions are very human-like in nature. See patents US 6,794,132, 6,680,209, 4,634,666, and Ostberg et al. (1983), *Hybridoma* 2:361-367, the contents of which are incorporated by reference.

For the generation of human antibodies, also see Mendez et al. *Nature Genetics* 15:146-156 (1997), Green and Jakobovits *J. Exp. Med.* 188:483-495 (1998), the disclosures of which are hereby incorporated by reference. Human antibodies are further discussed and delineated in U.S. patents 5,939,598 and 6,673,986. Also see US patents 6,114,598, 6,075,181, and 6,162,963, all filed Jun. 5, 1995. Also see US patent 6,150,584, filed Oct. 2, 1996 and US patents 6,713,610 and 6,657,103 as well as US patent applications 10/421,011 (US 2003-0229905 A1), 10/455,013 (US 2004-0010810 A1), 10/627,250 (US 2004-0093622 A1), 10/656,623 (US 2006-0040363 A1), 10/658,521 (US 2005-0054055 A1), 10/917,703 (US 2005-0076395 A1) and 10/978,297 (US 2005-0287630 A1). See also PCT/US93/06926 filed on July 23, 1993, European Patent No. EP 0 463 151 B1, grant published Jun. 12, 1996, International Patent Application No. WO 94/02602, published Feb. 3, 1994, International Patent Application No. WO 96/34096, published Oct. 31, 1996, and WO 98/24893, published Jun. 11, 1998. The disclosures of each of the above-cited patents, applications, and references are hereby incorporated by reference in their entirety.

In an alternative approach, others, including GenPharm International, Inc., have utilized a "minilocus" approach. In the minilocus approach, an exogenous Ig locus is mimicked through the inclusion of pieces (individual genes) from the Ig locus. Thus, one or more V_H genes, one or more D_H genes, one or more J_H genes, a mu constant region, and a second constant region (preferably a gamma constant region) are formed into a construct for insertion into an animal. This approach is described in U.S. Pat. No. 5,545,807 to Surani et al. and U.S. Pat. Nos. 5,545,806, 5,625,825, 5,625,126, 5,633,425, 5,661,016, 5,770,429, 5,789,650, and 5,814,318 each to Lonberg and Kay, U.S. Pat. No. 5,591,669 to Krimpenfort and Berns, U.S. Pat. Nos. 5,612,205, 5,721,367, 5,789,215 to Berns et al., and U.S. Pat. No. 5,643,763 to Choi and Dunn, and GenPharm International. Also see U.S. patents 5,569,825, 5,877,397, 6,300,129, 5,874,299, 6,255,458, and 7,041,871, the disclosures of which are hereby incorporated by reference. See also European Patent No. 0 546 073 B1, International

Patent Application Nos. WO 92/03918, WO 92/22645, WO 92/22647, WO 92/22670, WO 93/12227, WO 94/00569, WO 94/25585, WO 96/14436, WO 97/13852, and WO 98/24884, the disclosures of which are hereby incorporated by reference in their entirety. See further Taylor et al. (1992 Nucleic Acids Res. 20: 6287), Chen et al. (1993 Int. Immunol. 5: 647), Tuailon et al. (1993 Proc. Natl. Acad. Sci. USA 90: 3720-4), Choi et al., (1993 Nature Genetics 4: 117), Lonberg et al. (1994 Nature 368: 856-859), Taylor et al. (1994 International Immunology 6: 579-591), and Tuailon et al. (1995 J Immunol. 154: 6453-65), Fishwild et al. (1996 Nature Biotechnology 14: 845), and Tuailon et al. (2000 Eur J Immunol. 10: 2998-3005), the disclosures of which are hereby incorporated by reference in their entirety.

In certain embodiments, de-immunized anti-CD200 antibodies or antigen-binding fragments thereof are provided. De-immunized antibodies or antigen-binding fragments thereof may be modified so as to render the antibody or antigen-binding fragment thereof non-immunogenic, or less immunogenic, to a given species. De-immunization can be achieved by modifying the antibody or antigen-binding fragment thereof utilizing any of a variety of techniques known to persons skilled in the art (see e.g., PCT Publication Nos. WO 04/108158 and WO 00/34317). For example, an antibody or antigen-binding fragment thereof may be de-immunized by identifying potential T cell epitopes and/or B cell epitopes within the amino acid sequence of the antibody or antigen-binding fragment thereof and removing one or more of the potential T cell epitopes and/or B cell epitopes from the antibody or antigen-binding fragment thereof, for example, using recombinant techniques. The modified antibody or antigen-binding fragment thereof may then optionally be produced and tested to identify antibodies or antigen-binding fragments thereof that have retained one or more desired biological activities, such as, for example, binding affinity, but have reduced immunogenicity. Methods for identifying potential T cell epitopes and/or B cell epitopes may be carried out using techniques known in the art; such as, for example, computational methods (see e.g., PCT Publication No. WO 02/069232), *in vitro* or *in silico* techniques, and biological assays or physical methods (such as, for example, determination of the binding of peptides to MHC molecules, determination of the binding of peptide:MHC complexes to the T cell receptors from the species to receive the antibody or antigen-binding fragment thereof, testing of the protein or

peptide parts thereof using transgenic animals with the MHC molecules of the species to receive the antibody or antigen-binding fragment thereof, or testing with transgenic animals reconstituted with immune system cells from the species to receive the antibody or antigen-binding fragment thereof, etc.). In various embodiments, the de-immunized anti-CD200 antibodies described herein include de-immunized antigen-binding fragments, Fab, Fv, scFv, Fab' and F(ab')₂, monoclonal antibodies, murine antibodies, engineered antibodies (such as, for example, chimeric, single chain, CDR-grafted, humanized, fully human antibodies, and artificially selected antibodies), synthetic antibodies and semi-synthetic antibodies.

In a further embodiment, recombinant DNA comprising an insert coding for a heavy chain variable domain and/or for a light chain variable domain of antibodies directed to CD200 or a CD200-positive cell line are produced. The term DNA includes coding single stranded DNAs, double stranded DNAs consisting of said coding DNAs and of complementary DNAs thereto, or these complementary (single stranded) DNAs themselves.

Furthermore, DNA encoding a heavy chain variable domain and/or a light chain variable domain of antibodies directed to CD200 or the CD200-positive cell line can be enzymatically or chemically synthesized DNA having the authentic DNA sequence coding for a heavy chain variable domain and/or for the light chain variable domain, or a mutant thereof. A mutant of the authentic DNA is a DNA encoding a heavy chain variable domain and/or a light chain variable domain of the above-mentioned antibodies in which one or more amino acids are deleted, inserted, or exchanged with one or more other amino acids. Preferably said modification(s) are outside the CDRs of the heavy chain variable domain and/or of the light chain variable domain of the antibody in humanization and expression optimization applications. The term mutant DNA also embraces silent mutants wherein one or more nucleotides are replaced by other nucleotides with the new codons coding for the same amino acid(s). The term mutant sequence also includes a degenerate sequence. Degenerate sequences are degenerate within the meaning of the genetic code in that an unlimited number of nucleotides are replaced by other nucleotides without resulting in a change of the amino acid sequence originally encoded. Such degenerate sequences may be useful due to their different restriction sites and/or

frequency of particular codons which are preferred by the specific host, particularly *E. coli*, to obtain an optimal expression of the heavy chain variable domain and/or a light chain variable domain.

The term mutant is intended to include a DNA mutant obtained by in vitro mutagenesis of the authentic DNA according to methods known in the art.

For the assembly of complete tetrameric immunoglobulin molecules and the expression of chimeric antibodies, the recombinant DNA inserts coding for heavy and light chain variable domains are fused with the corresponding DNAs coding for heavy and light chain constant domains, then transferred into appropriate host cells, for example after incorporation into hybrid vectors.

Recombinant DNAs including an insert coding for a heavy chain variable domain of an antibody directed to CD200 or a CD200-positive cell line fused to a human constant domain IgG, for example $\gamma 1$, $\gamma 2$, $\gamma 3$ or $\gamma 4$; in particular embodiments $\gamma 1$ or $\gamma 4$ may be used. Recombinant DNAs including an insert coding for a light chain variable domain of an antibody directed to the cell line disclosed herein fused to a human constant domain κ or λ , preferably κ are also provided.

Another embodiment pertains to recombinant DNAs coding for a recombinant polypeptide wherein the heavy chain variable domain and the light chain variable domain are linked by way of a spacer group, optionally comprising a signal sequence facilitating the processing of the antibody in the host cell and/or a DNA sequence encoding a peptide facilitating the purification of the antibody and/or a cleavage site and/or a peptide spacer and/or an agent. The DNA coding for an agent is intended to be a DNA coding for the agent useful in diagnostic or therapeutic applications. Thus, agent molecules which are toxins or enzymes, especially enzymes capable of catalyzing the activation of prodrugs, are particularly indicated. The DNA encoding such an agent has the sequence of a naturally occurring enzyme or toxin encoding DNA, or a mutant thereof, and can be prepared by methods well known in the art.

Accordingly, the monoclonal antibodies or antigen-binding fragments of the disclosure can be naked antibodies or antigen-binding fragments thereof that are not conjugated to other agents, for example, a therapeutic agent or detectable label. Alternatively, the monoclonal antibody or antigen-binding fragment thereof can be conjugated to an agent such as, for example, a cytotoxic agent, a small molecule, a

hormone, an enzyme, a growth factor, a cytokine, a ribozyme, a peptidomimetic, a chemical, a prodrug, a nucleic acid molecule including coding sequences (such as antisense, RNAi, gene-targeting constructs, etc.), or a detectable label (e.g., an NMR or X-ray contrasting agent, fluorescent molecule, etc.). In certain embodiments, an anti-CD200 polypeptide or antigen-binding fragment (e.g., Fab, Fv, single-chain scFv, Fab' and F(ab')₂) is linked to a molecule that increases the half-life of said polypeptide or antigen-binding fragment. Molecules that may be linked to said anti-CD200 polypeptide or antigen-binding fragment include but are not limited to serum proteins including albumin, polypeptides, other proteins or protein domains, and PEG.

Several possible vector systems are available for the expression of cloned heavy chain and light chain genes in mammalian cells. One class of vectors relies upon the integration of the desired gene sequences into the host cell genome. Cells which have stably integrated DNA can be selected by simultaneously introducing drug resistance genes such as *E. coli* gpt (Mulligan, R. C. and Berg, P., Proc. Natl. Acad. Sci., USA, 78: 2072 (1981)) or Tn5 neo (Southern, P. J. and Berg, P., J. Mol. Appl. Genet., 1: 327 (1982)). The selectable marker gene can be either linked to the DNA gene sequences to be expressed, or introduced into the same cell by cotransfection (Wigler, M. et al., Cell, 16: 77 (1979)). A second class of vectors utilizes DNA elements which confer autonomously replicating capabilities to an extrachromosomal plasmid. These vectors can be derived from animal viruses, such as bovine papillomavirus (Sarver, N. et al., Proc. Natl. Acad. Sci., USA, 79: 7147 (1982)), polyoma virus (Deans, R. J. et al., Proc. Natl. Acad. Sci., USA, 81: 1292 (1984)), or SV40 virus (Lusky, M. and Botchan, M., Nature, 293: 79 (1981)).

Since an immunoglobulin cDNA is comprised only of sequences representing the mature mRNA encoding an antibody protein, additional gene expression elements regulating transcription of the gene and processing of the RNA are required for the synthesis of immunoglobulin mRNA. These elements may include splice signals, transcription promoters, including inducible promoters, enhancers, and termination signals. cDNA expression vectors incorporating such elements include those described by Okayama, H. and Berg, P., Mol. Cell Biol., 3: 280 (1983); Cepko, C. L. et al., Cell, 37: 1053 (1984); and Kaufman, R. J., Proc. Natl. Acad. Sci., USA, 82: 689 (1985).

In the therapeutic embodiments of the present disclosure, bispecific antibodies are contemplated. Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for the CD200 antigen on a cell (such as, e.g., a cancer cell or immune cell), the other one is for any other antigen, and preferably for a cell-surface protein or receptor or receptor subunit.

Methods for making bispecific antibodies are within the purview of those skilled in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities (Milstein and Cuello, *Nature*, 305:537-539 (1983)). Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, including at least part of the hinge, CH2, and CH3 regions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further details of illustrative currently known methods for generating bispecific antibodies see, for example, Suresh et al., *Methods in Enzymology*, 121:210 (1986); WO 96/27011; Brennan et al., *Science* 229:81 (1985); Shalaby et al., *J. Exp. Med.* 175:217-225 (1992); Kostelny et al., *J. Immunol.* 148(5):1547-1553 (1992); Hollinger et al., *Proc. Natl. Acad. Sci. USA* 90:6444-6448 (1993); Gruber et al., *J. Immunol.* 152:5368 (1994); and Tutt et al., *J. Immunol.* 147:60 (1991). Bispecific antibodies also include cross-linked or heteroconjugate antibodies. Heteroconjugate antibodies may be made using any convenient cross-linking methods. Suitable cross-linking agents are well known in the art, and are disclosed in U.S. Pat. No. 4,676,980, along with a number of cross-linking techniques.

Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny et al., *J. Immunol.*, 148(5):1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins may be linked to the Fab' portions of two different antibodies by gene

fusion. The antibody homodimers may be reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The "diabody" technology described by Hollinger et al., *Proc. Natl. Acad. Sci. USA* 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain (V_H) connected to a light-chain variable domain (V_L) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the V_H and V_L domains of one fragment are forced to pair with the complementary V_L and V_H domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (scFv) dimers has also been reported. See Gruber et al., *J. Immunol.*, 152:5368 (1994). Alternatively, the antibodies can be "linear antibodies" as described in Zapata et al. *Protein Eng.* 8(10):1057-1062 (1995). Briefly, these antibodies comprise a pair of tandem Fd segments (V_H - C_H1 - V_H - C_H1) which form a pair of antigen binding regions. Linear antibodies can be bispecific or monospecific.

In certain embodiments, the disclosure relates to fusion molecules wherein an anti-CD200 antibody or antigen-binding fragment is linked to a second molecule. Accordingly, the present disclosure provides anti-CD200 antibody conjugates. Anti-CD200 antibody conjugates comprise an antibody or antigen-binding portion of an anti-CD200 antibody and a heterologous moiety. The heterologous moiety may be a polypeptide (such as human serum albumin), a small molecule, a nucleic acid, a polymer (including natural and synthetic polymers such as PEG), metals, etc. The heterologous moiety may be a detectable or labeling moiety, such as a fluorescent or luminescent agent, or it may be a cytotoxic agent, an antibiotic, or a radioisotope or radionuclide. Antibody conjugates or fusion molecules of the present disclosure may therefore comprise, for example, a small molecule, polypeptide, peptidomimetic, heteroclitic peptide, a chemotherapeutic agent, an immunomodulatory agent, a targeting moiety, or a nucleic acid construct (e.g., antisense, RNAi, or gene-targeting construct).

In particular embodiments where increased integrity or longevity of an anti-CD200 antibody or fragment thereof is desired, the antibody or fragment thereof may

be conjugated to a molecule that will increase the half-life of the fragment in vivo. Such molecules include polymers such as PEG or other synthetic polymers—e.g., polyalkylene, polyalkenylene, polyoxyalkylene, etc. A fragment may alternatively be fused or otherwise linked to a polypeptide, protein domain, serum protein, or albumin. The antigen-binding fragment may be a Fab, Fv, single-chain fragments or scFv, Fab', F(ab')₂, or F(ab')₃, for example.

III. METHODS OF INHIBITING IMMUNE RESPONSES

A. Methods of Inhibiting a Humoral Immune Response

The immune system is capable of producing two types of antigen-specific responses to foreign antigens: cell-mediated immunity, which refers to effector functions of the immune system mediated by T lymphocytes, and humoral immunity, which refers to production of antigen-specific antibodies by B lymphocytes. Humoral immunity is mediated by activated B cells, which secrete antibodies specific to antigens on the surfaces of invading microbes, for example (such as viruses or bacteria). The antibodies bind to and target the invading microbes for destruction.

The development of humoral immunity against most antigens requires not only antibody-producing B cells or B lymphocytes but also the involvement of helper T (Th) cells or Th lymphocytes. (Mitchison, *Eur. J. Immunol.*, 1:18-25 (1971); Claman and Chaperon, *Transplant Rev.*, 1:92-119 (1969); Katz et al, *Proc. Natl. Acad. Sci. USA*, 70:2624-2629 (1973); Reff et al., *Nature*, 226:1257-1260 (1970)). Th cells provide certain signals in response to stimulation by thymus-dependent antigens. While soluble molecules released by Th cells (for instance cytokines such as IL-4 and IL-5) mediate some B lymphocyte activation, B cell activation also requires a contact-dependent interaction between B cells and Th cells (Hirohata et al., *J. Immunol.*, 140:3736-3744 (1988); Bartlett et al., *J. Immunol.*, 143:1745-1765 (1989); Brian, *Proc. Natl. Acad. Sci. USA*, 85:564-568 (1988); Hodgkin et al., *J. Immunol.*, 145:2025-2034 (1990); and Noelle et al, *J. Immunol.*, 146:1118-1124 (1991)).

The present disclosure demonstrates that administration of an anti-CD200 antibody inhibits B cell activity. Specifically, the disclosure shows that an anti-CD200 antibody can reduce the level of circulating immunoglobulin (e.g., IgG and IgM) following immune stimulation.

Accordingly, in certain embodiments, the present disclosure relates to methods and compositions for preventing or inhibiting a humoral immune response in a subject in need thereof comprising administering a CD200-binding agent. In certain embodiments, the binding agent is an anti-CD200 antibody or antigen-binding fragment thereof as described herein.

In some embodiments, administration of an anti-CD200 antibody is effective to inhibit B cells. For example, an anti-CD200 antibody of the present disclosure may be effective to target and/or inhibit circulating B cells and/or mature, antibody-secreting B cells. Accordingly, the methods and compositions of the disclosure may be effective to reduce or deplete circulating B cells as well as circulating immunoglobulin. In further embodiments, administration of an anti-CD200 antibody results in decreased levels of circulating IgG and/or IgM immunoglobulin.

While not wishing to be restricted to any particular mode of action, an anti-CD200 antibody may mediate ADCC, CDC, and/or apoptosis of B cells to which the antibody binds, as described elsewhere herein. The antibody may be a murine, chimeric, human, humanized, primatized, or de-immunized anti-CD200 antibody or antigen-binding fragment thereof. Optionally, the antibody may elicit increased effector function. However, as noted earlier, effector function, while possibly playing a role, is not the only means by which the desired effect is brought about.

A subject in need of prevention or inhibition of a humoral immune response may be, in certain embodiments, a patient with an autoimmune disorder or a transplant recipient. Accordingly, in certain embodiments the disclosure relates to immunotherapeutic compositions and methods for the treatment and prevention of graft versus host disease (GVHD) and graft rejection in patients wherein the compositions and methods comprise an agent that inhibits the interaction between CD200 and CD200R, preferably wherein said agent is an anti-CD200 antibody. In particular embodiments, the transplant recipient or patient with an autoimmune disorder is human. In further embodiments, the disclosure relates to methods for treating or preventing an acute or a chronic humoral rejection in a transplant recipient.

In certain embodiments, the agent, e.g., an anti-CD200 antibody, is used in combination with lower doses of traditional therapeutic drugs than would be possible in the absence of the agent (e.g., anti-CD200 antibody). In another embodiment, the

compositions and methods of the disclosure obviate the need for a more severe form of therapy, such as radiation therapy, high-dose immunomodulatory therapy, or splenectomy. Combination treatments are discussed in more detail below and include, for example, adriamycin, azathiopurine, busulfan, cyclophosphamide, cyclosporine A, Cytoxan, fludarabine, 5-fluorouracil, methotrexate, mycophenolate mofetil, a nonsteroidal anti-inflammatory, rapamycin, sirolimus, and tacrolimus. Other examples include antibodies such as, e.g., OKT3™ (muromonab-CD3), CAMPATH™-1G, CAMPATH™-1H (alemtuzumab), or CAMPATH™-1M, SIMULECT™ (basiliximab), ZENAPAX™ (daclizumab), RITUXAN™ (rituximab), and anti-thymocyte globulin.

In embodiments where an anti-CD200 is administered to a transplant recipient to inhibit a humoral immune response, the anti-CD200 antibody may be administered to a transplant recipient prior to or following transplantation, alone or in combination with one or more therapeutic agents or regimens for the treatment or prevention of GVHD and graft rejection. For example, an anti-CD200 antibody may be used to deplete alloantibodies from a transplant recipient prior to or following transplantation of an allogeneic graft. An anti-CD200 antibody may also be used to immuno-deplete CD200+ antibody-producing cells from the graft ex vivo, prior to transplantation, or in the donor, as prophylaxis against GVHD and graft rejection.

A transplant recipient in need of prophylaxis or treatment for humoral rejection may be identified according to the knowledge and skill in the art. For example, a transplant recipient in need of prophylaxis against graft rejection may be identified as a patient or patient population having detectable circulating anti-HLA alloantibodies prior to transplantation. In another example, the patient or patient population is identified as having panel reactive alloantibodies prior to transplantation. The presence of detectable circulating anti-HLA alloantibodies in a transplant recipient post-transplantation can also be used to identify a patient or patient population in need of treatment for humoral rejection according to the disclosure. The patient or patient population in need of treatment for humoral rejection can also be identified according to other clinical criteria that indicate that a transplant recipient is at risk for developing a humoral rejection or has already developed a humoral rejection. For example, a transplant recipient in need of

treatment for humoral rejection may be identified as a patient or patient population in an early stage of humoral rejection, such as a latent humoral response characterized by circulating anti-donor alloantibodies. An early stage humoral rejection may also be a silent reaction characterized by circulating anti-donor alloantibodies and C4d deposition, or a subclinical rejection characterized by circulating anti-donor alloantibodies, C4d deposition, and tissue pathology. In later stages, the recipient may be identified as a patient or patient population presenting with clinical indications of humoral rejection characterized according to the knowledge and skill in the art—for example, by circulating anti-donor alloantibodies, C4d deposition, tissue pathology, and graft dysfunction.

Anti-CD200 antibodies as described herein may be used to inhibit or prevent a humoral immune response in recipients of various kinds of transplanted cells, tissues, and organs. For example, a graft may be autologous, allogeneic, or xenogeneic to the recipient. The graft may be a cell, tissue, or organ graft, including, but not limited to, bone marrow grafts, peripheral blood stem cell grafts, skin grafts, arterial and venous grafts, pancreatic islet cell grafts, and transplants of the kidney, liver, pancreas, thyroid, and heart. In one embodiment, the autologous graft is a bone marrow graft, an arterial graft, a venous graft, or a skin graft. In another embodiment, the allograft is a bone marrow graft, a corneal graft, a kidney transplant, a heart transplant, a liver transplant, a lung transplant, a pancreatic transplant, a pancreatic islet cell transplant, or a combined transplant of a kidney and pancreas. In another embodiment, the graft is a xenograft, preferably wherein the donor is a pig. Further, an anti-CD200 antibody, used alone or in combination with a second agent, may also be used to suppress a deleterious immune response to a non-biological graft or implant, including, but not limited to, an artificial joint, a stent, or a pacemaker device.

Accordingly, the present disclosure relates to a method of inhibiting or preventing a humoral immune response (such as but not limited to humoral graft rejection) in a subject in need thereof comprising administering to the subject an agent which inhibits an interaction between CD200 and CD200R, e.g., anti-CD200 antibody, either alone or preferably in combination with one or more other therapeutic agents. In certain embodiments, the antibody is administered in an amount sufficient to decrease the number of circulating B cells and/or decrease the amount of

circulating immunoglobulin (e.g., IgG and/or IgM).

B. Methods of inhibiting a cellular immune response

Cellular immune responses are initiated when antigen-presenting cells present an antigen to CD4+ T helper (Th) lymphocytes resulting in T cell activation, proliferation, and differentiation of effector T lymphocytes (e.g., cytotoxic CD8+ T cells). Following exposure to antigens (such as exposure resulting from infection or the grafting of foreign tissue), naive T cells differentiate into Th1 and Th2 cells. Th1 cells produce IFN- γ and IL-2, both of which are associated with cell-mediated immune responses. Th1 cells play a role in immune responses commonly involved in the rejection of foreign tissue grafts as well as many autoimmune diseases. Th2 cells produce cytokines such as IL-4 and are associated with antibody-mediated immune responses (i.e., B cell-mediated responses) such as those responses commonly involved in allergies and allergic inflammatory responses such as asthma. Th2 cells may also contribute to the rejection of grafts. In numerous situations, a cellular immune response is desirable, for example, in defending the body against bacterial or viral infection, inhibiting the proliferation of cancerous cells and the like. However, in other situations, such effector T cells are undesirable, e.g., in a graft recipient.

Whether the immune system is activated by or tolerized to an antigen depends upon the balance between T effector cell activation and T regulatory cell activation. T regulatory cells are responsible for the induction and maintenance of immunological tolerance. These cells are T cells which produce low levels of IL-2, IL-4, IL-5, and IL-12. Regulatory T cells produce TNF α , TGF β , IFN- γ , and IL-10, albeit at lower levels than effector T cells. Although TGF β is the predominant cytokine produced by regulatory T cells, this cytokine is produced at lower levels than in Th1 or Th2 cells, e.g., an order of magnitude less than in Th1 or Th2 cells. Regulatory T cells can be found in the CD4+CD25+ population of cells (see, e.g., Waldmann and Cobbold. 2001 *Immunity* 14:399). Regulatory T cells actively suppress the proliferation and cytokine production of Th1, Th2, or naive T cells which have been stimulated in culture with an activating signal (e.g., antigen and antigen presenting cells or with a signal that mimics antigen in the context of MHC, e.g., anti-CD3 antibody, plus anti-CD28 antibody).

The present disclosure demonstrates that anti-CD200 antibody treatment reduces the number of activated CD4+ and CD8+ T cells following stimulation. Accordingly, the present disclosure relates to methods and compositions for preventing or inhibiting a cellular immune response in a subject in need thereof comprising administering a CD200-binding agent. In certain embodiments, the binding agent is an anti-CD200 antibody or antigen-binding fragment thereof as described herein.

In some embodiments, administration of an anti-CD200 antibody is effective to inhibit T cell activation and/or proliferation or to reduce the number of activated T cells. For example, an anti-CD200 antibody of the present disclosure may be effective to target and/or inhibit activated, CD200-expressing T cells, including Th1 and/or Th2 cells. Accordingly, the methods and compositions of the disclosure may be effective to reduce or deplete activated T cells as well as B cells that would otherwise be activated by Th2 cells (see discussion above). Accordingly, anti-CD200 inhibition of T cells may also result in a reduction of activated B cells and/or circulating immunoglobulin.

While not wishing to be restricted to any particular mode of action, an anti-CD200 antibody may mediate ADCC, CDC, and/or apoptosis of T cells to which the antibody binds, as described elsewhere herein. The antibody may increase the number or function of regulatory T cells. The antibody may be a murine, chimeric, human, humanized, primatized, or de-immunized anti-CD200 antibody or antigen-binding fragment thereof. Optionally, the antibody may elicit increased effector function.

A subject in need of prevention or inhibition of a cellular immune response may be, in certain embodiments, a patient with an autoimmune disorder or a transplant recipient. Accordingly, in certain embodiments the disclosure relates to immunotherapeutic compositions and methods for the treatment or prevention of graft versus host disease (GVHD) and graft rejection in patients, wherein the compositions and methods comprise an anti-CD200 antibody. In particular embodiments, the transplant recipient or patient with an autoimmune disorder is human. In further embodiments, the disclosure relates to methods for treating or preventing an acute or a chronic T cell-mediated rejection in a transplant recipient.

In certain embodiments, an anti-CD200 antibody is used in combination with lower doses of traditional therapeutic agents than would be possible in the absence of the anti-CD200 antibody. In another embodiment, the compositions and methods of the disclosure obviate the need for a more severe form of therapy, such as radiation therapy, high-dose immunomodulatory therapy (such as a high-dose of a therapy that targets T cells), or splenectomy. Combination treatments are discussed in more detail below and include, for example, adriamycin, azathiopurine, busulfan, cyclophosphamide, cyclosporine A, Cytoxan, fludarabine, 5-fluorouracil, methotrexate, mycophenolate mofetil, a nonsteroidal anti-inflammatory, rapamycin, sirolimus, and tacrolimus. Other examples include antibodies such as, e.g., OKT3 (muromonab-CD3), CAMPATH-1G, CAMPATH-1H (alemtuzumab), or CAMPATH-1M, SIMULEC (basiliximab), ZENAPAX (daclizumab), RITUXAN (rituximab), and anti-thymocyte globulin.

Accordingly, in embodiments where an anti-CD200 is administered to a transplant recipient to inhibit a cellular or T cell-mediated immune response, the anti-CD200 antibody may be administered to a transplant recipient prior to or following transplantation, alone or in combination with one or more other therapeutic agents or regimens for the treatment or prevention of GVHD and graft rejection. For example, an anti-CD200 antibody may be used to block or inhibit activation of T cells, to disrupt alloantigen presentation or to expand regulatory T cells.

C. Methods of Depleting or Eliminating Cells Overexpressing CD200

In accordance with the present disclosure, methods are provided for depleting cells that express CD200 in a subject by administering to the subject a therapy comprising a CD200-binding agent. As mentioned above, CD200 is expressed on certain immune cells. The disparate expression of CD200 provides an avenue by which to target activated immune cells (i.e., CD200-positive cells) for therapy. For example, CD200-positive immune cells may be targeted for depletion in methods of treating autoimmune disorders or graft rejection.

As discussed above, CD200, through its interaction with CD200R on myeloid cells, modulates immunosuppression by delivering an inhibitory signal for myeloid activity and/or migration. CD200-knockout mice, for example, demonstrate a more

active immune response following immunogenic stimuli (Hoek et al. *Science* 2000, 290:1768-1771), and CD200-expressing cells elicit immunosuppression by inducing a shift in the cytokine profile of stimulated immune cells. Specifically, CD200-positive cells are capable of inducing a shift from Th1 to Th2 cytokine production in mixed cell population assays. While CD200-positive cells are capable of suppressing the immune response, CD200-positive cells, accordingly, may be capable of escaping immune cell attack. However expression of CD200 on the membrane of immune cells can be exploited to target these cells in therapy. For example, an anti-CD200 antibody can specifically target CD200-positive cells and target CD200-positive cells to immune effector cells. The antibody may optionally disrupt the CD200:CD200R interaction. The embodiments of this disclosure, therefore, relate to methods of targeting CD200-positive cells for depletion comprising administering a CD200-binding agent.

In one aspect, the present disclosure relates to methods of modulating ADCC and/or CDC of CD200-positive target cells by administering a murine, chimeric, humanized, or human anti-CD200 antibody or fragment thereof to a subject in need thereof. The disclosure relates to variant anti-CD200 antibodies that elicit increased ADCC and/or CDC and to variant anti-CD200 antibodies that exhibit reduced or no ADCC and/or CDC activity.

IV. METHODS OF TREATING TRANSPLANT PATIENTS

The CD200-binding agents and polypeptides and/or antibodies utilized in the present disclosure are especially indicated for therapeutic applications as described herein. Accordingly, CD200-binding agents and anti-CD200 antibodies and variants thereof may be used in therapies, including combination therapies, in the diagnosis and prognosis of disease, as well as in the monitoring of disease progression.

While not wishing to be bound by any particular mechanism(s), an anti-CD200 antibody, antigen-binding fragment, polypeptide, or other CD200-binding agent may promote graft survival by eliminating CD200-positive cells, e.g., by binding to such cells and targeting these cells for immune attack and cell killing. For example, an anti-CD200 antibody or other binding agent may recruit effector cells or other ligands (e.g., complement component) to the CD200-positive cell to which the

antibody or binding agent is bound and target the CD200-positive cell for effector-mediated cell death.

In certain aspects, the disclosure relates to methods of treating patients who have received or will receive a transplant (e.g., a xenotransplant or allotransplant) comprising administering a CD200-binding agent. In certain embodiments, the binding agent is an anti-CD200 antibody or antigen-binding fragment thereof. Additionally, the antibody may be a murine, chimeric, humanized, human or de-immunized anti-CD200 antibody. Thus, methods of treating transplant patients may comprise any of the CD200-binding agents and antibodies set forth in the present disclosure.

In certain embodiments, anti-CD200 antibodies or CD200-binding agents may be used for depleting any type of cell that expresses CD200 on its surface, including for example, immune cells such as T-cells, B-cells, and dendritic cells. In one embodiment, anti-CD200 antibodies may be useful for targeted destruction of immune cells involved in an unwanted immune response, such as, for example, immune responses associated with transplant rejection. Exemplary immune responses that may be inhibited or prevented with the anti-CD200 antibodies provided herein include, for example, inflammatory responses (e.g., an anti-CD200 antibody may inhibit the production of inflammatory cytokines such as TNF- α and INF- γ), the production of antibodies specific to alloantigens and/or xenoantigens, and T-cell mediated responses.

In accordance with the methods and compositions described herein, therefore, the disclosure relates to methods of treating an allograft patient. An anti-CD200 antibody or other CD200-binding agent of the present disclosure may be administered to a patient prior to a transplant or allograft procedure or after the procedure in order to decrease or eliminate CD200-positive immune cells that could reduce the patient's acceptance of the transplanted organ, tissue, or cell. In a particular embodiment, an anti-CD200 antibody with increased effector function is given to a transplant patient.

Anti-CD200 antibodies of the present disclosure may be used for inhibiting rejection or promoting survival of a wide range of organ, tissue, and cell grafts as described above. The antibodies may also be used to inhibit graft versus host disease following bone marrow transplantation, for example.

In certain embodiments where the graft recipient is human, an allograft may be MHC mismatched. In certain embodiments, the MHC mismatched allograft is an HLA mismatched allograft. In further embodiments, the recipient is ABO mismatched to the allograft.

Therapies comprising CD200-binding agents or antibodies may be administered to patients in combination therapies. Accordingly, targeted killing of certain populations of immune cells for treating or preventing graft rejection, or for enhancing or extending transplant survival, may be administered as part of a combination therapy. For example, a patient receiving a first therapy comprising a CD200-binding agent (e.g., an anti-CD200 antibody described herein) may also be given a second therapy. The CD200-binding agent may be administered simultaneously with the second therapy. Alternatively, the CD200 antagonist may be administered prior to or following the second therapy. Second therapies include but are not limited to polypeptides, small molecules, chemicals, metals, organometallic compounds, inorganic compounds, nucleic acid molecules, oligonucleotides, aptamers, spiegelmers, antisense nucleic acids, locked nucleic acid (LNA) inhibitors, peptide nucleic acid (PNA) inhibitors, immunomodulatory agents, antigen-binding fragments, prodrugs, and peptidomimetic compounds. In particular embodiments, the second therapy comprises an anti-inflammatory agent, immunosuppressive agent, and/or anti-infective agent.

Combination therapies of the present disclosure include, for example, a CD200-binding agent as described herein (e.g., an anti-CD200 antibody or antigen-binding fragment thereof) administered concurrently or sequentially in series with steroids, anti-malarials, aspirin, non-steroidal anti-inflammatory drugs, immunosuppressants, or cytotoxic drugs. Included are corticosteroids (e.g. prednisone, dexamethasone, and prednisolone), methotrexate, methylprednisolone, macrolide immunosuppressants (e.g. sirolimus and tacrolimus), mitotic inhibitors (e.g. azathioprine, cyclophosphamide, and methotrexate), fungal metabolites that inhibit the activity of T lymphocytes (e.g. cyclosporine), mycophenolate mofetil, glatiramer acetate, and cytotoxic and DNA-damaging agents (e.g. chlorambucil). In certain embodiments, the immunosuppressive agent is selected from among OKT3 (muromonab-CD3), azathioprine, leflunamide, brequinar, ATG, ALG, 15-

deoxyspergualin, LF15-0195 (Tesch et al. *Kidney Int.* 2001 60(4):1354-65; Yang et al. *J. Leukocyte Biol.* 2003;74:438-447), CTLA-4-Ig (belatacept), rituxan, IVIg and bredinin. Anti-inflammatory agents include but are not limited to thalidomide and analogs thereof such as lenalidomide (Revlimid, CC-5013) and CC-4047 (Actimid). For allograft or transplant patients, for example, anti-CD200 therapy may be combined with antibody treatments including daclizumab, a genetically engineered human IgG1 monoclonal antibody that binds specifically to the α -chain of the interleukin-2 receptor, as well as various other antibodies targeting immune cells or other cells (e.g., anti-T cell antibodies). Such combination therapies may be useful in inhibiting immune responses. The disclosure also relates to therapies for transplant patients comprising a CD200-binding agent (such as, for example, the antibodies and variants thereof described in the present disclosure) conjugated to one or more agents.

In certain embodiments, more than one immunosuppressive drug is administered. In other embodiments, an immunomodulatory treatment method, e.g., plasmapheresis, splenectomy or immunoabsorption, is used in combination with an anti-CD200 antibody. Conversely, a combination therapy comprising an anti-CD200 antibody may eliminate the need for such a treatment.

In particular embodiments, an anti-CD200 antibody is administered in conjunction with an inhibitor of cellular immune function. Such inhibitors include but are not limited to cyclosporine A, tacrolimus, rapamycin, anti-T cell antibodies, daclizumab, and muromonab-CD3. As demonstrated in the present disclosure, a combination of an anti-CD200 antibody and an inhibitor of cellular immune function increases survival of a graft compared to the survival observed in a control graft recipient (e.g., a recipient receiving no treatment or a recipient receiving monotherapy, such as an inhibitor of cellular immune function). Increased survival includes, for example, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, or at least about 50% increase in survival time (measured in days, months, or years, for example).

In particular embodiments, a combination treatment comprising an anti-CD200 antibody and a T cell inhibitor leads to long-term survival of allografts. Long-term survival in humans includes, for example, at least about 5 years, at least about 7.5 years, and at least about 10 years survival post-transplant. In certain

embodiments, a combination treatment comprising an anti-CD200 antibody or antigen-binding fragment thereof and an inhibitor of T cell activity leads to accommodation of the graft.

While not wishing to be bound by any particular mechanism(s), in such combinations an inhibitor of cellular immune function may inhibit T cell responses and alter cytokine profiles while an anti-CD200 antibody inhibits antibody response and possibly also T cell responses. In particular embodiments, administration of an anti-CD200 antibody allows the successful use of a lower dose of an inhibitor of cellular immune function (e.g., cyclosporine A) than the dose that would otherwise be required to achieve the same or similar level of graft survival.

Accordingly, in certain aspects, the present disclosure relates to methods for enhancing the suppressive effect on graft rejection of existing immunosuppressive agents (cyclosporine, azathioprine, adrenocortical steroids, FK-506, etc.) using CD200-binding agents such as anti-CD200 antibodies and antigen-binding fragments thereof.

Depending on the nature of the combinatory therapy, administration of the anti-CD200 antibody may be continued while the other therapy is being administered and/or thereafter. Administration of the antibody may be made in a single dose, or in multiple doses. In some instances, administration of the anti-CD200 antibody is commenced at least several days prior to the conventional therapy, while in other instances, administration is begun either immediately before or at the time of the administration of the conventional therapy. In some cases, the anti-CD200 antibody will be administered after other therapies, or it could be administered alternating with other therapies.

In certain embodiments, the antibodies of the present disclosure may be used to deliver a variety of cytotoxic compounds. Any cytotoxic compound can be fused to the present antibodies. The fusion can be achieved chemically or genetically (e.g., via expression as a single, fused molecule). The cytotoxic compound can be a biological, such as a polypeptide, or a small molecule. As those skilled in the art will appreciate, for small molecules, chemical fusion is used, while for biological compounds, either chemical or genetic fusion can be employed.

Non-limiting examples of cytotoxic compounds include therapeutic drugs, a compound emitting radiation, molecules of plant, fungal, or bacterial origin, biological proteins, and mixtures thereof. The cytotoxic drugs can be intracellularly acting cytotoxic drugs, such as short-range radiation emitters, including, for example, short-range, high-energy α -emitters. Enzymatically active toxins and fragments thereof are exemplified by diphtheria toxin A fragment, nonbinding active fragments of diphtheria toxin, exotoxin A (from *Pseudomonas aeruginosa*), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, certain *Aleurites fordii* proteins, certain Dianthin proteins, *Phytolacca americana* proteins (PAP, PAPII and PAP-S), Morodica charantia inhibitor, curcin, crotin, *Saponaria officinalis* inhibitor, gelonin, mitogillin, restrictocin, phenomycin, and enomycin, for example. Procedures for preparing enzymatically active polypeptides of the immunotoxins are described in WO85/03508, which is hereby incorporated by reference. Certain cytotoxic moieties are derived from adriamycin, chlorambucil, daunomycin, methotrexate, neocarzinostatin, and platinum, for example.

Procedures for conjugating the antibodies with the cytotoxic agents have been previously described and are within the purview of one skilled in the art.

In another embodiment in accordance with the present disclosure, methods are provided for monitoring the progress and/or effectiveness of a therapeutic treatment. The method involves administering an immunomodulatory therapy and determining CD200 levels in a subject at least twice to determine the effectiveness of the therapy. For example, pre-treatment levels of CD200 can be ascertained and, after at least one administration of the therapy, levels of CD200 can again be determined. A decrease in CD200 levels is indicative of an effective treatment. Measurement of CD200 levels can be used by the practitioner as a guide for increasing dosage amount or frequency of the therapy. It should of course be understood that CD200 levels can be directly monitored or, alternatively, any marker that correlates with CD200 can be monitored.

V. MODES OF ADMINISTRATION AND FORMULATIONS

The route of antibody administration of the antibodies of the present disclosure (whether the pure antibody, a labeled antibody, an antibody fused to a

toxin, etc.) is in accord with known methods, e.g., injection or infusion by intravenous, intraperitoneal, intracerebral, intramuscular, subcutaneous, intraocular, intraarterial, intrathecal, inhalation or intralesional routes, or by sustained release systems. The antibody is preferably administered continuously by infusion or by bolus injection. One may administer the antibodies in a local or systemic manner.

The present antibodies may be prepared in a mixture with a pharmaceutically acceptable carrier. Techniques for formulation and administration of the compounds of the instant application may be found in "Remington's Pharmaceutical Sciences," Mack Publishing Co., Easton, PA, latest edition. This therapeutic composition can be administered intravenously or through the nose or lung, preferably as a liquid or powder aerosol (lyophilized). The composition may also be administered parenterally or subcutaneously as desired. When administered systemically, the therapeutic composition should be sterile, substantially pyrogen-free and in a parenterally acceptable solution having due regard for pH, isotonicity, and stability. For example, a pharmaceutical preparation is substantially free of pyrogenic materials so as to be suitable for administration as a human therapeutic. These conditions are known to those skilled in the art.

According to the compositions and methods set forth in the present embodiments, the disclosure relates to any pharmaceutical composition comprising an anti-CD200 antibody. Included are chimeric, humanized, human and de-immunized anti-CD200 antibodies and antigen-binding fragments, including single-chain antibodies. Also included are murine, chimeric, humanized, human and de-immunized variant anti-CD200 antibodies and antigen-binding fragments with altered effector function(s) as described herein. Pharmaceutical compositions of the disclosure may further comprise one or more immunomodulatory or immunosuppressive agents, such as an inhibitor of T cell function.

Pharmaceutical compositions suitable for use include compositions wherein one or more of the present antibodies are contained in an amount effective to achieve their intended purpose. More specifically, a therapeutically effective amount means an amount of antibody effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated or to prolong the survival of the grafted organ, tissue or cells. Determination of a therapeutically effective

amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein. Therapeutically effective dosages may be determined by using in vitro and in vivo methods.

In certain aspects, the disclosure provides the use of a CD200-binding agent and an immunomodulatory or immunosuppressive agent in the manufacture of a medicament or medicament package for prolonging survival of or inhibiting disease in a subject in need thereof (e.g., a graft recipient). In certain embodiments, more than one immunosuppressive agent is included in the medicament or medicament package. In certain embodiments, the binding agent (e.g., an anti-CD200 antibody or fragment thereof) and the immunomodulatory or immunosuppressive agent are in a formulation suitable for concurrent administration to the subject in need thereof. In certain embodiments, the binding agent (e.g., an anti-CD200 antibody or fragment thereof) and the immunomodulatory or immunosuppressive agent are in a formulation or formulations suitable for sequential administration to the subject in need thereof. In certain embodiments, an anti-CD200 antibody or antigen-binding fragment thereof is in a formulation suitable for chronic administration to the subject in need thereof. In certain embodiments, the immunomodulatory or immunosuppressive agent is in a formulation suitable for chronic administration to a subject in need thereof, such as a graft recipient.

In certain embodiments, a CD200-binding agent is an antibody in a lyophilized formulation comprising the antibody and a lyoprotectant. In certain embodiments, an immunomodulatory or immunosuppressive agent of the disclosure is in a lyophilized formulation comprising the immunosuppressive agent and a lyoprotectant. In certain embodiments, the antibody and immunosuppressive agent are in the same lyophilized formulation comprising said antibody, said immunosuppressive drug, and a lyoprotectant. In certain embodiments, a CD200-binding agent such as an anti-CD200 antibody is in an injection system comprising a syringe that comprises a cartridge, wherein the cartridge contains the antibody in a formulation suitable for injection. In certain embodiments, an immunomodulatory or immunosuppressive agent is in an injection system comprising a syringe that comprises a cartridge, wherein the cartridge contains the immunomodulatory or immunosuppressive agent in a formulation suitable for injection. In certain

embodiments, an anti-CD200 antibody and an immunomodulatory or immunosuppressive agent are in an injection system comprising a syringe that comprises a cartridge, wherein said cartridge contains the antibody and the immunomodulatory or immunosuppressive agent in a formulation suitable for injection. The antibody and or the immunomodulatory or immunosuppressive agent may be in unit dosage form(s). Accordingly, the present disclosure provides methods of inhibiting immune responses, including humoral and cellular responses, and methods of inhibiting graft rejection, or of prolonging survival of transplanted cells, tissues or organs. In particular, methods of prolonging survival of allografted cells, tissues or organs are provided. These methods are directed to using a CD200-binding agent, such as an anti-CD200 antibody, optionally in combination with one or more immunosuppressants and/or immunosuppressive methods. The disclosure also provides use of a CD200-binding agent, such as an anti-CD200 antibody, optionally with one or more immunosuppressants, in the manufacture of one or more medicaments or medicament packages. Such medicaments or medicament packages are useful in inhibiting immune responses, such as in a patient with an autoimmune disorder or in a transplant recipient.

VI. EXEMPLIFICATION

EXAMPLE 1

T cell killing by antibody hB7V3V2

To evaluate whether incubation of activated T cells with anti-CD200 antibodies containing a constant region mediating effector function (e.g. an IgG1 constant region) results in the killing of the T cells, T cells were activated and killing assays were set up as described below.

A. CD3+ T cell isolation

Human peripheral blood lymphocytes (PBLs) were obtained from normal healthy volunteers by density gradient centrifugation of heparinized whole blood using the Accuspin™ System. Fifteen mL of Histopaque-1077 (Sigma, St. Louis, MO; cat# H8889) was added to each Accuspin tube (Sigma, St. Louis, MO; cat#

A2055) which was then centrifuged at 1500 rpm for 2 minutes so that the Histopaque was allowed to pass through the frit. Thirty mL of whole blood was layered over the frit and the tubes were centrifuged for 15 minutes at 2000 rpm at room temperature with no brake. The PBL interface was collected and mononuclear cells were washed twice in PBS with 2% heat-inactivated fetal bovine serum (FBS) (Atlas Biologicals, Ft. Collins, CO; cat# F-0500-D) with 1200 rpm centrifugation for 10 minutes. CD3+ T cells were isolated by passage over a HTCC-5 column (R&D Systems) according to the manufacturer's instructions. Eluted cells were washed, counted and resuspended in RPMI 1640 containing 5% heat-inactivated single donor serum, 2 mM L-glutamine, 10 mM Hepes and penicillin/streptomycin.

B. Activation with plate-bound mOKT3

Wells of 12-well plates (Falcon) were coated by overnight incubation at 4°C with 10 µg/mL mOKT3 (Orthoclone) diluted in PBS. Residual antibody was removed and the plates gently rinsed with PBS. Purified CD3+ T cells, isolated as described above, were added to the plates at a final concentration of 2×10^6 /well in RPMI 1640 containing 5% heat-inactivated single donor serum, 2 mM L-glutamine, 10 mM Hepes and penicillin/streptomycin. Cells were maintained for 72 hours at 37°C in a humidified incubator containing 5% CO₂.

C. ⁵¹Chromium labeling of mOKT3-activated CD3+ target cells

At the end of the culture period, mOKT3-activated CD3+ cells were harvested, washed and resuspended at 10^7 cells/mL in RPMI 1640 without serum. Cells were chromated by the addition of 125 µCi of ⁵¹Chromium (Perkin Elmer, Billerica, MA)/ 10^6 cells for 2 hours at 37°C. Labeled cells were harvested, washed in RPMI containing 5% heat-inactivated single donor serum and resuspended at a final concentration of 2×10^5 cells/mL in the same medium.

D. Preparation of autologous NK effector cells

Human peripheral blood lymphocytes (PBLs) from the same individual were obtained as described above by density gradient centrifugation. The PBL interface was collected and mononuclear cells were washed twice in PBS with 2% heat-

inactivated fetal bovine serum (FBS) (Atlas Biologicals, Ft. Collins, CO; cat# F-0500-D) with 1200 rpm centrifugation for 10 minutes. CD56+ cells were isolated by positive selection over anti-CD56-conjugated magnetic beads (Miltenyi Biotec, Auburn, CA, Cat # 120-000-307) according to the manufacturer's instructions. Eluted cells were washed, counted and resuspended at 1.3×10^6 cells/mL in RPMI 1640 containing 5% heat-inactivated single donor serum, 2 mM L-glutamine, 10 mM Hepes and penicillin/streptomycin. Cells were incubated overnight at 37°C in a humidified incubator containing 5% CO₂ at a final concentration of 4×10^6 cells/well in 3 mL of the same medium. At the end of the culture period, the cells were harvested, washed, counted and resuspended in serum-free RPMI containing 2 mM L-glutamine, 10 mM Hepes, 2×10^{-5} M 2-mercaptoethanol and penicillin/streptomycin.

E. ADCC assay

⁵¹Cr-labelled mOKT3-activated CD3+ target cells prepared as described above were distributed in wells of a 96-well plate at 10^4 cells/well in 50 µL. CD56+ effector cells were harvested, washed, counted and resuspended at either 2.5×10^6 cells/mL (for an effector:target cell ratio of 25:1) or 10^6 cells/mL (for an effector:target cell ratio of 10:1) and were distributed (100 µL/well) to wells containing the target cells. Ten-fold dilutions of anti-CD200 antibodies (V3V2-G1 or V3V2-G2/G4) were added to the effectors and targets at final concentrations of 10, 1, 0.1 and 0.01 µg/mL. Assay controls included the following: 1) effectors and targets in the absence of antibody (0 Ab); 2) target cells in the absence of effectors (spontaneous lysis) and 3) effectors and targets incubated with 0.2% Tween-80 (maximum release). All cell culture conditions were performed in triplicate. Cells were incubated at 37°C for 4 hours in a humidified incubator containing 5% CO₂. At the end of the culture period, the plates were centrifuged to pellet the cells and 150 µL of cell supernatant was transferred to scintillation vials and counted in a gamma scintillation counter (Wallac). The results are expressed as percent specific lysis according to the following formula:

$$\frac{(\text{Mean sample counts per minute (cpm)} - \text{mean spontaneous lysis})}{(\text{mean maximum lysis} - \text{mean spontaneous lysis})} \times 100$$

F. Flow cytometry

One hundred μ L of cell suspensions (mOKT3-activated CD3+ cells or purified CD56+ NK cells) prepared as described above were distributed to wells of a 96-well round bottom plate (Falcon, Franklin Lakes NJ; cat# 353077). Cells were incubated for 30 minutes at 4°C with the indicated combinations of the following fluorescein isothiocyanate (FITC)-, Phycoerythrin (PE)-, PerCP-Cy5.5-, or allophycocyanin (APC)-conjugated antibodies (all from Becton-Dickinson, San Jose, CA); anti-human CD25-FITC (cat# 555431); anti-human CD3-APC (cat# 555335); anti-human CD200-PE (cat # 552475); anti-human CD8-PerCP-Cy5.5 (cat# 341051); anti-human CD4-APC (cat# 555349); anti-human CD5-APC (cat# 555355) and anti-human CD56-APC (cat# 341025). Isotype controls for each labeled antibody were also included. After washing cells twice with FACS buffer (1800 rpm centrifugation for 3 minutes), cells were resuspended in 300 μ L of PBS (Mediatech, Herndon, VA; cat# 21-031-CV) and analyzed by flow cytometry using a FACSCalibur machine and CellQuest Software (Becton Dickinson, San Jose, CA).

As shown in Figure 5, activated T cells show high CD200 expression on their surface. Activated T cells are efficiently killed in the presence of hB7V3V2-G1 but not hB7V3V2-hG2G4 when NK cells are used as effector cells (Figure 6). These data demonstrate that anti-CD200 antibodies with effector function can eliminate activated T cells. Such an antibody can be of therapeutic use in the transplantation setting or for the treatment of autoimmune diseases.

In addition to regulatory T cells, plasmacytoid dendritic cells have been shown to play a negative immunoregulatory role in human cancer (Wei S, et al., *Cancer Res.* 2005 Jun 15; 65(12):5020-6). Combination of a therapy eliminating plasmacytoid dendritic cells with anti-CD200 therapy can therefore be advantageous.

EXAMPLE 2

Anti-CD200 mAb prevents acute allograft rejection in a mouse cardiac transplantation model

The calcineurin inhibitors, such as cyclosporine A (CsA) and tacrolimus, are known to have narrow therapeutic ranges. Even at therapeutic doses, these drugs carry a considerable risk for nephrotoxicity (Seron, D., and F. Moreso. 2004,

Transplant Proc 36:257S). Treatment with subtherapeutic levels of either CsA or tacrolimus results in significantly lower incidence of nephrotoxicity but at the same time shows marked graft rejection (Seron, D., and F. Moreso, 2004. *Transplant Proc* 36:257S; Dunn et al., 2001, *Drugs* 61:1957; Scott et al. 2003 *Drugs* 63:1247). The limitations and side effects of current therapy regimens indicate that it is of value to search for novel drugs that reduce the requirement of CsA and have synergy with low dose CsA to prevent acute rejection and prolong graft survival.

The present study examined graft survival in a C57BL/6-to-BALB/c fully MHC-mismatched mouse heart transplantation model. Each experimental group consisted of five animals. Treatments were administered as follows:

- Anti-CD200 mAb: 100 µg/mouse/day, days 0-14, i.p.
- Rapamycin (Rapa): 2 mg/kg/day, days 0-13, orally
- Cyclosporine A (CsA):
 - Low dose/long-term treatment: 5mg/kg/day, days 0-endpoint, s.c.
 - High dose/long-term treatment: 15mg/kg/day, days 0-endpoint, s.c.
 - High dose/short-term treatment: 15mg/kg/day, days 0-28, s.c.

The anti-CD200 mAb used was OX90mG2a, a chimeric antibody derived from OX90, a rat anti-mouse CD200 mAb obtained as a hybridoma from the European Collection of Cell Cultures (ECACC No. 03062502; see Hoek et al., *Science* 290:1768-1771 (2000)). The rat antibody was genetically modified to contain the rat heavy chain variable regions fused to a murine IgG2a constant region and the rat light chain variable region fused to a murine kappa constant region. The antibody used to obtain the data for Table 1 was obtained from a different antibody preparation than the preparation from which the antibody in Table 2 was obtained. Table 2 additionally includes data using an antibody called OX90NE. Antibody OX90NE is a rat anti-mouse CD200 antibody that has been engineered to have decreased effector function. This was accomplished by mutating four amino acid residues of OX90mG2a heavy chain (the light chains are identical). The sequences of OX90mG2a and OX90NE are shown in Figure 10. The various OX90 antibodies are blocking antibodies, as shown in Figure 11. Cells of the A20 line, which express high levels of

murine CD200, were incubated with 20 μ g/mL 12B4 (control) or OX90 variant antibodies for 30 minutes at 4°C. Cells were washed and incubated with 10 μ g/mL CD200R1-Fc conjugated with R-PE (Invitrogen/molecular probes, catalog Z 25155) for 30 minutes at 4°C. Binding was analyzed by flow cytometry. As shown, OX90hG2G4, OX90NE and OX90mG2a efficiently block the binding of R-PE labeled CD200R1-Fc to CD200 on A20 cells, whereas the control antibody 12B4 does not block binding.

Graft histology

At necropsy, heart tissue samples were fixed in 10% buffered formaldehyde, embedded in paraffin and sectioned for hematoxylin and eosin (H&E) staining. The microscopic sections were examined in a blinded fashion for severity of rejection by a pathologist (B.G.). Criteria for graft rejection included the presence of vasculitis, thrombosis, hemorrhage and lymphocyte infiltration and were scored as: 0, no change; 1, minimum change; 2, mild change; 3, moderate change; or 4, marked change compared to normal tissues.

Immunohistochemistry

Four micrometer sections were cut from cardiac frozen tissue samples embedded in Tissue-Tek Optimum Cutting Temperature (O.C.T.) gel (Skura Finetek, Torrance, CA), mounted on gelatin-coated glass microscope slides and stained by a standard indirect avidin-biotin immunoperoxidase method using an Elite Vectastain ABC kit (Vector Laboratories Inc., Burlingame, CA). Specimens were evaluated for the presence of CD4⁺ and CD8⁺ T cells using a biotin-conjugated rat anti-mouse CD4 mAb (clone YTS 191.1.2, Cedarlane Laboratories Ltd., Hornby, Ontario, Canada) and a biotin-conjugated rat anti-mouse CD8 mAb (clone 53-6.7, BD Biosciences, Franklin Lakes, NJ), respectively. Intragraft monocyte/macrophage infiltration was detected with a biotin-conjugated rat anti-mouse Mac-1 mAb (Cedarlane). Mouse IgG and IgM deposition was detected in grafts using biotin-conjugated goat anti-mouse-IgG and goat anti-mouse-IgM, respectively (Cedarlane). For identification of complement deposition, tissue sections were sequentially incubated with polyclonal goat anti-mouse C3 or anti-mouse C5 sera (Quidel, San Diego, CA), biotinylated rabbit anti-goat IgG (Vector Laboratories), and HRP-conjugated-streptavidin (Zymed

Laboratories, South San Francisco, CA). Slides were washed with phosphate-buffered saline (PBS) between the antibody incubation steps and examined under light microscopy. Negative controls were performed by omitting the primary antibodies. Antibody reactivity was evaluated in five high-powered fields of each section using tissue samples from five animals per treatment group. The intensity of staining was graded from 0 to 4+ according to the following: 0, negative; 1+, equivocal; 2+, weak; 3+, moderate and 4+, intensive staining.

Table 1: Experimental Groups and Survival Data

Treatment	Individual survival (days)	MST ± SD (days)
1) Untreated	8, 8, 9, 9 (Historical data)	8.5 ± 0.6
2) CsA (Low dose/long-term)	9, 10, 10, 10, 11, 11 (Historical data)	10.1 ± 0.3
3) CsA (High dose/long-term)	15, 16, 16, 17 (Historical data)	16 ± 0.8
4) OX90mG2a	8, 9, 9, 9, 10, 11	9
5) OX90mG2a + CsA (High dose/long-term)	>100 x 4	>100
6) OX90mG2a + CsA (High dose/short-term)	56 (B), 71 (B), 75 (B)	71
7) OX90mG2a + CsA (Low dose/long-term)	53, 54, 54, >76 (A), >76 (A), >81 (A-), >81 (A-)	>76
8) OX90mG2a + Rapa	>100 x 6	>100

* The degree of pulsation is scored as: A, beating strongly; B, mild decline in the intensity of pulsation; C, noticeable decline in the intensity of pulsation; or D, complete cessation of cardiac impulses. MST = Mean Survival Time; SD = Standard Deviation.

Table 2: Heart Graft Survival:

Groups	Individual Survival*	Median Survival (days)
1) OX90mG2a	9, 10, 10, 11	10
2) OX90mG2a + CsA (Low dose/long-term)	13#, 13#, 14#, 31#, 40**, 75, 78	75
3) OX-90NE + CsA (Low dose/long-term)	14#, 16#, 39, 39, 64, 67, 68	64
4) Isotype control (12B4) + CsA (Low dose/long-term)	12, 12, 13, 14	12.5

* The degree of pulsation is scored as: A, beating strongly; B, mild decline in the intensity of pulsation; C, noticeable decline in the intensity of pulsation; or D, complete cessation of cardiac impulses.

** Animal died with strong beating of heart graft

As mentioned above, unexpected early rejection may be due to a possible problem with this batch of antibody.

The heart grafts in the Isotype control (12B4) group were rejected rapidly. Further, no difference was observed in the survival time between Isotype control (12B4) + CsA group and CsA monotherapy group. The data in Tables 1 and 2 demonstrate that anti-CD200 therapy has a strong effect in prolonging survival. This was seen both with an antibody having effector function and an antibody lacking effector function.

Table 3: Median scores of histological changes of heart allografts at necropsy (study endpoint or at time of rejection)*

Groups	Vasc	Infar	Lymph	Throm	Hemo
1) Untreated (POD8/endpoint)	3.0	3.0	3.0	4.0	3.0
2) CsA (High dose/long-term, POD16/endpoint)	2.0	1.0	2.0	3.0	2.0
3) CsA (low dose/short-term)	3.0	2.0	2.0	4.0	2.0
4) OX90mG2a (POD9/endpoint)	2.0	1.0	2.0	3.0	2.0
5) OX90mG2a + CsA (High dose/long-term, POD100)	0.0	1.0	1.0	1.0	0.0
6) OX90mG2a + (High dose/short-term)	2.0	0.0	2.0	0.0	1.0
7) OX90mG2a + CsA (Low dose/long-term)	1.0	1.0	2.0	1.0	1.0
8) OX90NE + CsA (Low dose/long-term)	2.0	1.0	2.0	1.0	2.0
9) Isotype control (12B4) + CsA (Low dose/long-term)	2.0	2.0	2.0	3.0	2.0

*Median scores: 0 - normal; 1- minimal change; 2 - mild change; 3 - moderate change; 4 - marked change. POD = Post Operative Day.

In addition to survival and graft survival, circulating anti-donor antibody levels and the number of T cell populations in the spleen were measured by flow cytometry. Anti-CD200 mAb in combination with a high dose of CsA inhibits anti-donor antibody production in long-term surviving recipients (Figures 7A and 7B). Further, anti-CD200 mAb in combination with a high dose of CsA significantly downregulates splenic CD4+ and CD8+ T cell populations in long-term surviving recipients (Figure 8).

Additionally, the following cell populations were measured by flow

cytometry: CD3CD200; CD3CD200R; CD19CD200; CD19CD200R; CD11cCD200; and CD11cCD200R. These results are shown in Figures 9A-C.

Intragraft deposition of IgG, IgM, C3 and C5 and other intragraft cellular markers (such as CD4, CD8, and Mac-1) were measured in frozen graft sections. The results are shown in Tables 4-6.

Table 4: Intragraft Deposition of Humoral Markers Detected by Immunohistochemistry

Frozen sections of the grafts were collected and stained (for the sacrificed animals only)

Groups (Treatment)	IgG	IgM	C3	C5
1) Untreated	4+	2+	3+	3+
2) CsA (High dose/long-term)	3+	2+	3+	3+
3) CsA (Low dose/long-term)	3+	2+	3+	3+
4) OX90mG2a	2+	2+	3+	3+
5) OX90mG2a + CsA (High dose/long-term, POD 100)	1+	1+	3+	2.5+
6) OX90mG2a + CsA (High dose/short-term)	2+	2+	3+	3+
7) OX90mG2a + CsA (Low dose/long-term)	2+	2+	3+	3+
8) OX90NE + CsA (Low dose/long-term)	2+	2+	3+	3+
9) Isotype control (12B4) + CsA (Low dose/long-term)	2+	2+	3+	3+

Staining intensity grades: 0 is negative, 1+ is equivocal, 2+ is weak, 3+ is moderate, and 4+ is intense.

Table 5: Intragraft Cellular Markers Measured by Immunohistochemistry
 Frozen sections of the grafts were collected and stained (for the sacrificed animals only)

Groups (Treatment)	CD4	CD8	Mac
1) Untreated	3+	2+	3+
2) CsA (High dose/long-term)	2+	2+	3+
3) CsA (Low dose/long-term)	2+	2+	3+
4) OX90mG2a	2+	1+	3+
5) OX90mG2a + CsA (High dose/long-term, POD 100)	1+	1+	1+
6) OX90mG2a + CsA (High dose/short-term)	2+	2+	2+
7) OX90mG2a + CsA (Low dose/long-term)	2+	1+	2+
8) OX90NE + CsA (Low dose/long-term)	2+	2+	3+
9) Isotype control (12B4) + CsA (Low dose/long-term)	2+	2+	3+

Staining intensity grades: 0 is negative, 1+ is equivocal, 2+ is weak, 3+ is moderate, and 4+ is intense.

Table 6: Intragraft CD200 and CD200R Deposition Measured by Immunohistochemistry

Frozen sections of the grafts were collected and stained (for the sacrificed animals only).

Groups (Treatment)	CD200	CD200R
1) Untreated	3+	2+
2) CsA (High dose/long-term)	3+	2+
3) CsA (Low dose/long-term)	3+	2+
4) OX90mG2a	2+	1+
5) OX90mG2a + CsA (High dose/long-term, POD 100)	2+	1+
6) OX90mG2a + CsA (High dose/short-term)	2+	1+
7) OX90mG2a + CsA (Low dose/long-term)	2+	1+
8) OX90NE + CsA (Low dose/long-term)	2+	1+
9) Isotype control (12B4) + CsA (Low dose/long-term)	3+	2+

Staining intensity grades: 0 is negative, 1+ is equivocal, 2+ is weak, 3+ is moderate, and 4+ is intense.

The data above demonstrate that an anti-CD200 mAb in combination with CsA significantly prolongs heart allograft survival in a mouse cardiac transplantation model. Importantly, anti-CD200 mAb significantly reduces the requirement of CsA in achieving long-term allograft acceptance.

EXAMPLE 3

Effect of Anti-CD200 mAb, OX90NE-AG, in Prevention of Acute Allograft Rejection

The OX90NE antibody described above was originally thought to lack effector function, however, it was later found that OX90NE still retained some effector

function and thus further experiments were performed with a different antibody, OX90NE-AG that lacks effector function. The OX90NE-AG antibody is similar to the OX90NE antibody but includes one additional mutation which replaces the Asn 298 residue with Gln. The AG designates that the antibody is aglycosylated (the Asn298 can be glycosylated but the Gln298 cannot be glycosylated); the resulting antibody cannot mediate ADCC or CDC.

Similar to the experiments described above, the present study examined graft survival in a C57BL/6-to-BALB/c fully MHC-mismatched mouse heart transplantation model. Each experimental group consisted of five animals. Treatments were administered as follows:

- OX90NE-AG: 100 µg/mouse/day, days 0-14, i.p.
- Cyclosporine A (CsA): 15mg/kg/day, days 0-endpoint, s.c.

The results are shown below in Table 7.

Table 7: Experimental groups and survival results

Groups	Individual survival days*
CsA+OX90NE-AG variant (Sacrificed on POD16)	16 (A) x 5
CsA+OX90NE-AG variant (to be sacrificed on POD100)	> 90 (A), >90 (A), >90 (A), >90 (A), >90 (A)
High dose/long-term treatment	

* The degree of pulsation is scored as: A, beating strongly; B, mild decline in the intensity of pulsation; C, noticeable decline in the intensity of pulsation; or D, complete cessation of cardiac impulses. MST = Mean Survival Time; SD = Standard Deviation; POD = Post Operative Days.

All 10 mice used in this study were treated identically. Five mice were sacrificed after day 16 for the purpose of further analyses such as those shown in Tables 3-6. The other 5 mice remained alive at day 90 and will be sacrificed at day 100, at which point analyses similar to those found in Tables 3-6 will be performed for both groups of mice sacrificed at day 16 and day 100.

It will be understood that various modifications may be made to the

embodiments disclosed herein. For example, as those skilled in the art will appreciate, the specific sequences described herein can be altered slightly without necessarily adversely affecting the functionality of the polypeptide, antibody or antibody fragment used in binding OX-2/CD200. For instance, substitutions of single or multiple amino acids in the antibody sequence can frequently be made without destroying the functionality of the antibody or fragment. Thus, it should be understood that polypeptides or antibodies having a degree of identity greater than 70% to the specific antibodies described herein are within the scope of this disclosure. In particularly useful embodiments, antibodies having an identity greater than about 80% to the specific antibodies described herein are contemplated. In other useful embodiments, antibodies having an identity greater than about 90% to the specific antibodies described herein are contemplated. Therefore, the above description should not be construed as limiting, but merely as exemplifications of preferred embodiments. Those skilled in the art will envision other modifications within the scope and spirit of this disclosure.

REFERENCES

The following references are incorporated herein by reference to more fully describe the state of the art to which the present disclosure pertains. Any inconsistency between these publications below or those incorporated by reference above and the present disclosure shall be resolved in favor of the present disclosure.

- 1) Agarwal, et al. (2003). Disregulated expression of the Th2 cytokine gene in patients with intraoral squamous cell carcinoma. *Immunol Invest* 32:17-30.
- 2) Almasri, NM et al. (1992). *Am J Hematol* 40: 259-263.
- 3) Contasta, et al., (2003). Passage from normal mucosa to adenoma and colon cancer: alteration of normal sCD30 mechanisms regulating TH1/TH2 cell functions. *Cancer Biother Radiopharm* 18:549-557.
- 4) Gorczynski, et al. (1998). Increased expression of the novel molecule OX-2 is involved in prolongation of murine renal allograft survival. *Transplantation* 65:1106-1114.
- 5) Gorczynski, et al. (2001). Evidence of a role for CD200 in regulation of immune rejection of leukaemic tumour cells in C57BL/6 mice. *Clin Exp Immunol* 126:220-229.

- 6) Hainsworth, JD (2000). *Oncologist* 2000; 5(5):376-84.
- 7) Inagawa, et al. (1998). Mechanisms by which chemotherapeutic agents augment the antitumor effects of tumor necrosis factor: involvement of the pattern shift of cytokines from Th2 to Th1 in tumor lesions. *Anticancer Res* 18:3957-3964.
- 8) Ito, et al. (1999). Lung carcinoma: analysis of T helper type 1 and 2 cells and T cytotoxic type 1 and 2 cells by intracellular cytokine detection with flow cytometry. *Cancer* 85:2359-2367.
- 9) Kiani, et al. (2003). Normal intrinsic Th1/Th2 balance in patients with chronic phase chronic myeloid leukemia not treated with interferon-alpha or imatinib. *Haematologica* 88:754-761.
- 10) Lauerova, et al. (2002). Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response. *Neoplasma* 49:159-166.
- 11) Maggio, et al. (2002). Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues. *Ann Oncol* 13 Suppl 1:52-56.
- 12) Nilsson, K (1992). *Burn Cell*. 5(1):25-41.
- 13) Podhorecka, et al. (2002). T type 1/type 2 subsets balance in B-cell chronic lymphocytic leukemia--the three-color flow cytometry analysis. *Leuk Res* 26:657-660.
- 14) Pu, QQ and Bezwoda, W (2000). *Anticancer Res*. 20(4):2569- 78.
- 15) Smyth, et al. (2003). Renal cell carcinoma induces prostaglandin E2 and T-helper type 2 cytokine production in peripheral blood mononuclear cells. *Ann Surg Oncol* 10:455-462.
- 16) Tatsumi, et al. (2002). Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. *J Exp Med* 196:619-628.
- 17) Walls, et al. (1989). *Int. J Cancer* 44:846-853.
- 18) Winter, et al. (2003). Tumour-induced polarization of tumour vaccine-draining lymph node T cells to a type 1 cytokine profile predicts inherent strong immunogenicity of the tumour and correlates with therapeutic efficacy in adoptive transfer studies. *Immunology* 108:409-419.
- 19) Cameron, et al. 2005. Myxoma virus M141R expresses a viral CD200 (vOX-

2) that is responsible for down-regulation of macrophage and T-cell activation in vivo. *J Virol* 79:6052.

20) Foster-Cuevas, et al. 2004. Human herpesvirus 8 K14 protein mimics CD200 in down-regulating macrophage activation through CD200 receptor. *J Virol* 78:7667.

21) Nicholas, J. 2003. Human herpesvirus-8-encoded signalling ligands and receptors. *J Biomed Sci* 10:475.

22) Shiratori, et al. 2005. Down-regulation of basophil function by human CD200 and human herpesvirus-8 CD200. *J Immunol* 175:4441.

23) Voigt, et al. 2005. The English strain of rat cytomegalovirus (CMV) contains a novel captured CD200 (vOX2) gene and a spliced CC chemokine upstream from the major immediate-early region: further evidence for a separate evolutionary lineage from that of rat CMV Maastricht. *J Gen Virol* 86:263.

24) Zhang, et al. 2005. Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 replication and transcription activator regulates viral and cellular genes via interferon-stimulated response elements. *J Virol* 79:5640.

CLAIMS:

1. A method of inhibiting an immune response in a subject in need thereof, wherein said method comprises administering to the subject an effective amount of i) an agent which inhibits interaction between CD200 and CD200R and ii) an immunosuppressive or immunomodulatory drug, wherein said agent is an antibody, or an antigen-binding fragment thereof, which (a) binds to CD200 and (b) exhibits reduced ADCC or CDC activity or no ADCC or CDC activity.
2. The method of claim 1, wherein said immune response is a humoral response.
3. The method of claim 1 or claim 2, wherein said immune response is an antibody mediated response.
4. The method of any one of claims 1 to 3, wherein said immunosuppressive drug is cyclosporine A or rapamycin.
5. The method of any one of claims 1 to 4, wherein said antibody or antigen-binding fragment thereof is selected from the group consisting of a human antibody or antigen-binding fragment thereof, a humanized antibody or antigen-binding fragment thereof, a primatized antibody or antigen-binding fragment thereof, a chimeric antibody or antigen-binding fragment thereof, a murine antibody or antigen-binding fragment thereof, and a de-immunized antibody or antigen-binding fragment thereof.
6. The method of any one of claims 1 to 4, wherein said antigen-binding fragment is selected from the group consisting of single-chain antibody, Fab, Fab', F(ab')₂, F(ab')₃, Fd, Fv, and a domain antibody.
7. The method of any one of claims 1 to 3, 5 or 6, wherein said immunomodulatory or immunosuppressive drug is a calcineurin inhibitor.
8. The method of claim 7, wherein said calcineurin inhibitor is selected from the group consisting of tacrolimus and cyclosporine A.
9. The method of any one of claims 1 to 3, 5 or 6, wherein said immunomodulatory

or immunosuppressive drug is selected from the group consisting of adriamycin, azathiopurine, busulfan, cyclophosphamide, cyclosporine A, fludarabine, 5-fluorouracil, methotrexate, mycophenolate mofetil, a nonsteroidal anti-inflammatory, sirolimus (rapamycin), and tacrolimus (FK-506).

10. The method of any one of claims 1 to 3, 5 or 6, wherein said immunomodulatory or immunosuppressive drug is an antibody selected from the group consisting of muromonab-CD3, alemtuzumab, basiliximab, daclizumab, rituximab, and anti-thymocyte globulin.
11. The method of any one of claims 1 to 10, wherein said subject is human.
12. The method of claim 11, wherein said subject has received or will receive a cell, tissue or organ transplant.
13. The method of claim 12, wherein said method prevents graft rejection or promotes graft survival.
14. The method of claim 12, wherein said method comprises administering to said subject said agent and said drug prior to receiving said cell, tissue or organ transplant.
15. The method of any one of claims 1 to 14, wherein said agent is administered i) prior to said drug, ii) subsequently to said drug, or iii) simultaneously with said drug.
16. The method of claim 12, wherein said method comprises administering said agent during a rejection episode of said cell, tissue or organ transplant.
17. The method of claim 13, wherein said graft rejection is an acute or a chronic humoral rejection of a grafted cell, tissue, or organ.
18. The method of claim 12, wherein said subject is a recipient of a hematopoietic cell or bone marrow transplant, an allogenic transplant of pancreatic islet cells, or a solid organ transplant selected from the group consisting of a heart, a kidney-pancreas, a kidney, a liver, a lung, and a pancreas.

19. The method of any one of claims 1 to 18, wherein said method results in a decrease in the production of anti-donor antibodies.
20. The method of claim 13, wherein said graft rejection is an acute graft rejection in a graft recipient of cell, tissue or organ allo- or xenotransplant.
21. The method of claim 13, wherein said graft rejection is a chronic graft rejection in a graft recipient of cell, tissue or organ allo- or xenotransplant.
22. The method of claim 12, wherein said method promotes long-term graft survival, wherein said long-term graft survival is selected from the group consisting of:
 - (a) at least 6 months post transplant;
 - (b) at least 1 year post transplant; and
 - (c) at least 5 years post transplant.
23. The method of claim 22, wherein said method promotes accommodation of the transplanted cell, tissue or organ.
24. The method of any one of claims 1 to 11, wherein said subject has an antibody mediated inflammatory disease or an autoimmune disease.
25. The method of claim 24, wherein said autoimmune disease is an autoimmune hemolytic anemia.
26. The method of any one of claims 1 to 25, wherein said agent is administered systemically.
27. The method of any one of claims 1 to 25, wherein said agent is administered locally.
28. The method of any one of claims 1 to 27, wherein said immune response is a primary response.
29. The method of any one of claims 1 to 27, wherein said immune response is a secondary response.

30. A method of decreasing what constitutes an effective amount of an immunosuppressive or immunomodulatory drug administered to a subject, said method comprising administering to said subject i) said immunosuppressive or immunomodulatory drug and ii) an agent which inhibits interaction between CD200 and CD200R, wherein less of said drug is required to effect immunosuppression or immunomodulation as compared to administering said drug without said agent, and wherein said agent is an antibody, or an antigen-binding fragment thereof, which (a) binds to CD200 and (b) exhibits reduced ADCC or CDC activity or no ADCC or CDC activity.
31. The method of claim 30, wherein said subject has received or will receive an allograft.
32. The method of claim 30, wherein said subject has an autoimmune disease or an antibody mediated inflammatory disease.
33. The method of any one of claims 30 to 32, wherein said drug is cyclosporine A or rapamycin.
34. A method of inhibiting rejection of an allograft in an allograft recipient during a rejection episode, said method comprising administering to said allograft recipient an effective amount of an agent which inhibits interaction between CD200 and CD200R, wherein rejection of said allograft is inhibited, and wherein said agent is an antibody, or an antigen-binding fragment thereof, which (a) binds to CD200 and (b) exhibits reduced ADCC or CDC activity or no ADCC or CDC activity.
35. The method of any one of claims 1 to 29, wherein said antibody is a variant of a naturally-occurring antibody.
36. The method of any one of claims 30 to 33, wherein said antibody is a variant of a naturally-occurring antibody.
37. The method of claim 34, wherein said antibody is a variant of a naturally-occurring antibody.
38. The method of claim 35, wherein said antibody comprises a variant Fc constant

region that has ADCC activity or CDC activity equal to or less than the ADCC activity or CDC activity the antibody would have if it had a Fc constant region comprising: (a) a glutamic acid substitution at amino acid position 236, (b) a glutamine substitution at amino acid position 298, and (c) an alanine substitution at amino acid positions 319, 321, and 323, wherein each substitution is relative to the amino acid sequence depicted in SEQ ID NO:28.

39. The method of claim 36, wherein said antibody comprises a variant Fc constant region that has ADCC activity or CDC activity equal to or less than the ADCC activity or CDC activity the antibody would have if it had a Fc constant region comprising: (a) a glutamic acid substitution at amino acid position 236, (b) a glutamine substitution at amino acid position 298, and (c) an alanine substitution at amino acid positions 319, 321, and 323, wherein each substitution is relative to the amino acid sequence depicted in SEQ ID NO:28.
40. The method of claim 34 or claim 37, wherein said antibody comprises a variant Fc constant region that has ADCC activity or CDC activity equal to or less than the ADCC activity or CDC activity the antibody would have if it had a Fc constant region comprising: (a) a glutamic acid substitution at amino acid position 236, (b) a glutamine substitution at amino acid position 298, and (c) an alanine substitution at amino acid positions 319, 321, and 323, wherein each substitution is relative to the amino acid sequence depicted in SEQ ID NO:28.
41. Use of an agent which inhibits interaction between CD200 and CD200R in the preparation of a medicament for inhibiting an immune response in a subject, wherein said medicament is adapted to be administered in combination with an immunosuppressive or immunomodulatory drug, and wherein said agent is an antibody, or an antigen-binding fragment thereof, which (a) binds to CD200 and (b) exhibits reduced ADCC or CDC activity or no ADCC or CDC activity.
42. Use of an agent which inhibits interaction between CD200 and CD200R in the preparation of a medicament for immunosuppression or immunomodulation, wherein said medicament is adapted to be administered in combination with an immunosuppressant or immunomodulatory drug, wherein less of said drug is required to effect said immunosuppression or immunomodulation as compared to

administering said drug without said medicament, and wherein said agent is an antibody, or an antigen-binding fragment thereof, which (a) binds to CD200 and (b) exhibits reduced ADCC or CDC activity or no ADCC or CDC activity.

43. Use of an agent which inhibits interaction between CD200 and CD200R in the preparation of a medicament for inhibiting rejection of an allograft in an allograft recipient during a rejection episode, wherein said agent is an antibody, or an antigen-binding fragment thereof, which (a) binds to CD200 and (b) exhibits reduced ADCC or CDC activity or no ADCC or CDC activity.
44. A method of inhibiting an immune response; a method of decreasing what constitutes an effective amount of an immunosuppressive or immunomodulation drug administered to a subject; a method of inhibiting rejection of an allograft; or use of an agent which inhibits interaction between CD200 and CD200R in the preparation of a medicament, substantially as herein described with reference to any one or more of the examples but excluding comparative examples.

FIGURE 1A-1F

FIGURE 1A Note: Figs. 1-4, leader sequences (AA) are underlined and constant regions are in bold.

chC2aB7-hG1**Heavy chain (introns in hG1) (SEQ ID NO. 1)**

MGWSCIILFLVATATGVHSLEVQLQQSGPELVKPGASLKMSCKASGYSFT
DYIILWVKQNHGKSLEWIGHIDPYYGSSNYNLKFKGKATLTVDKSSSTAY
MQLNSLTSEDSAVYYCGRSKRDYFDYWQGTTLVSSASTKGPSVFPLA
PSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPALQSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHT
CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEV
KFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE
YKCKVSNKALPAPIEKTI**SKAKGQPREPQVYTLPPSREEMTKNQVSLT**
CLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDK
WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

FIGURE 1B**(SEQ ID NO. 2) (genomic sequence hG1)**

ATGGGATGGAGCTGTATCATCCTCTTGGTAGCAACAGCTACAGGTGTCCACTCCCTCGAG
GTCCAGCTGCAACAGTCTGGACCTGAGCTGGTGAAGCCTGGGCTTCACTGAAGATGTCCTGC
AAGGCTTCTGGTTATTCACTCACTGACTACATCATACTCTGGGTGAAGCAGAACCATGGAAAG
AGCCTTGAGTGGATTGGACATATTGATCCTTACTATGGTAGTTCAACTACAATCTGAAATTCA
AGGGCAAGGCCACATTGACTGTAGACAAATCTTCAGCACAGCCTACATGCAGCTAACAGT
CTGACATCTGAGGACTCTGCAGTCTATTACTGTGAAGATCTAAGAGGGACTACTTGACTAC
TGGGCCAAGGCCACACTCTCACAGTTCCAGCCTCCACCAAGGGCCATCGGTCTTCCCC
CTGGCACCCCTCCCAAGAGCACCTCTGGCGGCACAGCGGCCCTGGCTGCCTGGTCAAGGAC
TACTTCCCCAACCGGTGACGGTGTGTAACCTAGGCGCCCTGACCAGCGGTGACACC
TTCCCGGCTGTCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCTCCA
GCAGCTTGGGACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGAACACCAAGGTG
GACAAGAGAGTTGGTGAGAGGCCAGCACAGGGAGGGAGGGTCTGCTGGAAGGCCAGGCTC
AGCGCTCCTGCCTGGACGCATCCCGCTATGCAGTCCAGGGCAGCAAGGCAGGCC
CGTCTGCCTCTTCACCCGGAGGCCTCTGCCGCCACTCATGCTCAGGGAGAGGGTCTTCTG
GCTTTTCCCCAGGCTCTGGCAGGCACAGGCTAGGTGCCCTAACCCAGGCCCTGCACACAA
AGGGCAGGTGCTGGCTCAGACCTGCCAAGAGCCATATCCGGAGGACCCCTGCCCTGACC
TAAGCCCACCCAAAGGCCAAACTCTCACTCCCTCAGCTCGGACACCTCTCCTCCCCAGA
TTCCAGTAACTCCAAATCTCTCTGCAGAGCCAAATCTTGACAAAACACACATGCC
ACCGTGCCAGGTAAGCCAGCCCAGGCCTGCCCTCCAGCTCAAGGGAGGACAGGTGCCCTA
GAGTAGCCTGCATCCAGGGACAGGCCAGCCGGTGCTGACACGTCCACCTCCATCTTCC
TCAGCACCTGAACTCCTGGGGGACCGTCAGTCTCCTCTTCCCCAAAACCCAAGGACACC
CTCATGATCTCCGGACCCCTGAGGTCACATCGTGGTGACCGTGGAGGTGCATAATGCCAAGAACAGCCGCG
GAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGAACAGCCGCG
GGAGGAGCAGTACAACACAGCAGTACCGTGTGGTCAGCGTCCTCACGTCTGCACCAAGGACT
GGCTGAATGGCAAGGAGTACAAGTGCAGGTCTCAACAAAGCCCTCCAGGCCCATCGAG
AAAACCATCTCCAAAGCCAAGGTGGACCCGTGGGTGCGAGGGCACATGGACAGAGGCC
GGCTCGGCCACCCCTGCCCTGAGAGTGACCGCTGTACCAACCTCTGCCCTACAGGGCAGC
CCCGAGAACCCACAGGTGTACCCCTGCCCTCCAGGAGATGACCAAGAACAGGTC
AGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATGCCGTGGAGTGGAGAGCAAT
GGCAGCCGGAGAACAACTACAAGACCACGCCCTCCGTGCTGGACTCCGACGGCTCCTTCTC
CTCTATAGCAAGCTACCGTGGACAAGAGCAGGTGGCAGCAGGGAACGTCTCTCATGCTCC
GTGATGCATGAGGCTCTGCACAACCAACTACACGCAGAAGAGCCTCTCCCTGCCCCGGTAAA
TGA

FIGURE 1C: A schematic representation of the heavy chain of antibody chC2aB7-hG1.




FIGURE 1D**Light Chain (human Ck) (SEQ ID NO. 4)**

MGWSCIILFLVATATGVHSRDIQMTQSPSSMYASLGERVTITCKASQDINSYL
SWFQQKPGKSPKTLIYRANRLVDGVPSRFSGSGQDYSLTISSEYEDMGIY
YCLQYDEFPYTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNN
FYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLTSKADYE
KHKVYACEVTHQGLSSPVTKSFNRGEC

FIGURE 1E**(SEQ ID NO. 5)**

ATGGGATGGAGCTGTATCATCCTCTTGGTAGCAACAGCTACAGGTGT
CCACTCTAGAGACATCCAGATGACACAGTCTCCATCTTCCATGTATGCATC
TCTAGGAGAGAGAGTCACTATCACTTGCAAGGCGAGTCAGGACATTAATA
GCTATTTAACAGCTGGTCCAGCAGAAACCAGGGAAATCTCTAACAGACCCTG
ATCTATCGTCAAACAGATTGGTAGATGGGTTCCATCAAGGTTAGTGG
CAGTGGATCTGGCAAGATTATTCTCTACCACAGCAGCCTGGAGTATG
AAGATATGGGAATTATTATTGTCTACAGTATGATGAGTTCCGTACACGT
TCGGAGGGGGGACCAAGCTGGAAATAAACGGACTGTGGCTGCACCATC
TGTCTTCATCTCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTC
TGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGGCAAAGTACAGT
GGAAGGTGGATAACGCCCTCCAATGGGTAACTCCCAGGAGAGTGTAC
AGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCTGACG
CTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCA
CCCATCAGGGCCTGAGCTGCCCGTCACAAAGAGCTTCAACAGGGAGA
GTGTTAA

FIGURE 1F: A schematic representation of the light chain of antibody chC2aB7-hG1.




FIGURE 2A-2F

FIGURE 2A**chC2aB7-hG2G4****Heavy chain (SEQ ID NO. 7)**

MGWSCIILFLVATATGVHSLEVQLQQSGPELVKPGASLKMSCKASGYSFT
DYIILWVKQNHGKSLEWIGHIDPYYGSSNYNLKFKGKATLTVDKSSSTAY
MQLNSLTSEDSAVYYCGRSKRDYFDYWQGTTLTVSSASTKGPSVFPLA
PCSRSTSESTAALGCLVKDYFPEPVTSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECP
PCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFN
WYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKC
KVSNKGLPSSIEKTISKAKGQPREPVYTLPPSQEEMTKNQVSLTCLV
KGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSRLTVDKSR
WQEGNVFSCSVMHEALHNHYTQKSLSLSGK

FIGURE 2B**(SEQ ID NO. 8) (genomic sequence hG2G4)**

ATGGGATGGAGCTGTATCATCCTCTTGGTAGCAACAGCTACAGGTGTCCACTCCCTCGAG
GTCCAGCTGCAACAGTCTGGACCTGAGCTGGTGAAGCCTGGGCTTCACTGAAGATGTCCTGC
AAGGCTCTGGTTATTCACTCACTACATCATACTCTGGGTGAAGCAGAACCATGGAAAG
AGCCTTGAGTGGATTGGACATATTGATCCTTACTATGGTAGTTCTAACTACAATCTGAAATTCA
AGGGCAAGGCCACATTGACTGTAGACAAATCTCCAGCACAGCCTACATGCAGCTAACAGT
CTGACATCTGAGGACTCTGCAGTCTATTACTGTGGAAGATCTAAGAGGGACTACTTGACTAC
TGGGCCAAGGCACCACTCTCACAGTTCCCTCAGCCTCCACCAAGGGCCATCCGTCTCCCC
CTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGA
CTACTTCCCCGAACCGGTGACGGTGTGTAACCTCAGGCGCCCTGACCAGCGCGTGCACAC
CTTCCCGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCC
AGCAACTTCGGCACCCAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGT
GGACAAGACAGTTGGTGAGAGGCCAGCTCAGGGAGGGAGGGTGTCTGCTGGAAGCCAGGCTC
AGCCCTCCTGCCCTGGACCCACCCCGCTGTCAGCCCCAGGCCAGGGCAGCAAGGCAGGCC
CATCTGTCTCCTCACCGGAGGCCTCTGCCCGCCCCACTCATGCTCAGGGAGGGTCTTCTG
GCTTTTCCACCAGGCTCAGGCAGGCACAGGCTGGGTGCCCTACCCAGGCCCTTCACACA
CAGGGCAGGTGCTGGCTCAGACCTGCCAAAGCCATATCGGGAGGACCCCTGCCCTGAC
CTAAGCCGACCCCAAAGGCCAAACTGTCCACTCCCTCAGCTCGGACACCTCTCTCCCTCCAG
ATCCGAGTAACCTCAATCTTCTCTGCAGAGCGCAAATGTTGTGTCAGTGCCACCGTGC
CCAGGTAAGCCAGCCCAGGCCTGCCCTCCAGCTCAAGGCAGGACAGGTGCCCTAGAGTAGC
CTGCATCCAGGGACAGGCCAGCTGGGTGTCAGACGGTCCACCTCCATCTTCCCTCAGCAC
CACCTGTGGCAGGACCGTCAGTCTCCTCTTCCCCAAAACCCAAGGACACCCCTCATGATCT
CCCGGACCCCTGAGGTACGTGCGTGGTGAGGTGCAATGCCAAGACAAAGCCGGAGGAGCA
TTCAACTGGTACGTGGATGGGTGGAGGTGCAATGCCAAGACAAAGCCGGAGGAGCA
GTTCAACAGCACGTACCGTGTGGTACGCGTCTCAGCGTCCACCGTCTGCAACAGGACTGGTGAACGG
CAAGGAGTACAAGTGCAGGTCTCAACAAAGGCCTCCGTCTCCATCGAGAAAACCATCT
CCAAAGCCAAAGGTGGACCCACGGGTGCGAGGCCACATGGACAGAGGTCACTCGGCC
ACCCCTGCCCTGGAGTGACCGCTGTGCCAACCTCTGCCCTACAGGGCAGCCCCGAGAGCC
ACAGGTGTACCCCTGCCCTACCCAGGAGGAGATGACCAAGAACCCAGGTCACTGCC
GCCTGGTCAAAGGCTTCTACCCAGCGACATGCCGTGGAGTGGAGAGCAATGGCAGCC
GAGAACAACTACAAGACCAAGCAGCCTCCGTGCTGGACTCCGACGGCTCTTCTCTACAGC
AGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGAAATGTCTCATGCTCCGTGATGCA
TGAGGCTCTGCACAACCACTACACACAGAACGCTCCCTGTCTGGGTAAATGA

FIGURE 2C: A schematic representation of the heavy chain of antibody chC2aB7-hG2G4 (amino acids 1-337).

FIGURE 2D**Light Chain (human Ck) (SEQ ID NO. 11)**

MGWSCIILFLVATATGVHSRDIQMTQSPSSMYASLGERVTITCKASQDINS
YLSWFQQKPGKSPKTLIYRANRLVDGVPSRFSGSGSGQDYSLTISSELEYED
MGIYYCLQYDEFPYTFGGGTKLEIKRTVAAPSVIFPPSDEQLKSGTASV
VCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSL
TLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

FIGURE 2E**(SEQ ID NO. 12)**

ATGGGATGGAGCTGTATCATCCTCTTGGTAGCAACAGCTACAGGT
GTCCACTCTAGAGACATCCAGATGACACAGTCTCCATCTTCCATGTAT
GCATCTCTAGGAGAGAGAGTCACTATCACTTGCAAGGCGAGTCAGGA
CATTAATAGCTATTAAGCTGGTCCAGCAGAAACCAGGGAAATCTCC
TAAGACCCCTGATCTATCGTGCAAACAGATTGGTAGATGGGTTCCATC
AAGGTTCACTGGCAGTGGATCTGGCAAGATTATTCTCTCACCATCAG
CAGCCTGGAGTATGAAGATATGGGAATTATTATTGTCTACAGTATGA
TGAGTTCCGTACACGTTGGAGGGGGACCAAGCTGGAAATAAAAAC
GGACTGTGGCTGCACCATCTGCTTCATCTTCCGCCATCTGATGAGCA
GTTGAAATCTGGAACTGCCTCTGTTGTGCCTGCTGAATAACTCTAT
CCCAGAGAGGCCAAAGTACAGTGGAAAGGTGGATAACGCCCTCCAATC
GGGTAACTCCCAGGAGAGTGTACAGAGCAGGACAGCAAGGACAGCA
CCTACAGCCTCAGCAGCACCCCTGACGCTGAGCAAAGCAGACTACGAG
AAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTC
GCCCGTCACAAAGAGCTAACAGGGGAGAGTGTAA

FIGURE 2F: A schematic representation of the light chain of antibody chC2aB7-hG2G4.

XbaI

AAGCTTGGCGCCACCATGGGATGGAGCTGTATCATCCTCTTCTGGTAGAACAGCTACAGGTGTCACCTAGAGAGATCCAGATGACACAGTCTCCAT 100
 M G W S C I I L F L V A T A T G V H S R D I C M T O S P
 leader _____ re _____ mVL

CTTCATSTATCCATCTCTAGGAGAGAGTCACTATCACTTGCAAGGGGGACTCAGGACATTAATACGTTATTTAAGCTGGTCCACCCAGAAACAGGGAA 200
 S S H Y A S L G E R V T I T C K A S O D E I N S Y L S W F G O K P G K
 mVL

ATCTCTTAAGACCTGATCTATCGCAAAACAGATTCGATAGGGTTCTATCAAGGTTAGTGGAGTGGATCTGGCAAGATTAATCTACCAAC 300
 S P K T L I Y R A N R L V D O C V P S R F S C S G S G O D Y S L I I
 mVL

AGCAGCTGGAGATGAAGATAGGAAATTATTATTCAGTATGATGAGTTCCGTACACGTTGGAGGGGGACCAAGCTGGAAATAAAACGGA 400
 S S L E Y E D M G I Y Y C L O Y D E F P Y T F G G G T K L E I K R I
 mVL

CTGTGGCTSCACCATCTGCTTCATCTTCCGCCATCTGATGAGCAGTTGAAATCTGGAACGCCCTGTGTGTCCTGCTGAATAACCTCTATCCAG 500
 T V A A P S V F I F P P S D E O L K S C T A S V V C L L N N F Y P R
 hCK

AGAGGCCAAAGTACAGTGGAAAGGTGGATAACGCCCTCCAATCGGCTAACTCCAGGAGAGTGTCAACAGAGCAGGACAOCAAGGACAGCACCTACAGCTC 600
 E A K Y D W K Y O N A L O S G N S O E S Y T E O D S K D S T Y S L
 hCK

NotI

TCAACAGGGAGACTGTCACCGGGCCCAATTCAATTCA 738
 F N P G E C S A A A I H
 hCK _____ +6AA _____

FIGURE 3A-3F

FIGURE 3A**hB7V3V2-hG1****Heavy chain (SEQ ID NO. 15)**

MGWSRIFLFLSIIAGVHCQVQLQQSGSELKKPGASVKISCKASGYSFTDY
IILWVRQNPKGLEWIGHIDPYYGSSNYNLKFGRVTITADQSTTAYME
LSSLRSEDTAVYYCGRSKRDYFDYWGQGTTLVSSASTKGPSVFPLAPSS
KSTSGGTAAAGCLVKDYFPEPVTWNSGALTSGVHTFPAVLQSSGL
YSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCP
PCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF
NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK
CKVSNKALPAPIEKTIISKAKGQPREPVYTLPPSREEMTKNQVSLTCL
VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR
WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

FIGURE 3B**(SEQ ID NO. 16) (cDNA hG1)**

ATGGGATGGAGCCGGATCTTCTCTCCTGTCAATAATTGCAGGTG
TCCATTGCCAGGTCCAGCTGCAACAGTCTGGATCTGAGCTGAAGAAGC
CTGGGGCTTCAGTGAAGATCTCCTGCAAGGCTCTGGTTATTCATTAC
TGACTACATCATACTCTGGGTGAGGCAGAACCCCTGGAAAGGGCCTG
GTGGATTGGACATATTGATCCTACTATGGTAGTTCTAACTACAATCTG
AAATTCAAGGGCAGAGTGACAATCACCGCCGACCAGTCTACCAC
AGCCTACATGGAGCTCTCAGTCTGAGATCTGAGGACACTGCAGTCTA
TTACTGTGGAAGATCTAAGAGGGACTACTTGACTACTGGGGCCAAGG
CACCACTCTCACAGTTCCCTCAGCCTCCACCAAGGGCCATCGGTCTC
CCGCTAGCACCCCTCCTCCAAGAGCACCTCTGGGGCACAGCGGCCCTG
GGCTGCCTGGTCAAGGACTACTTCCCCAACCGGTGACGGTGTGCGTGG
AACTCAGGCGCCCTGACCAGCGCGTGCACACCTCCCGCTGTCCTA
CAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCC
AGCAGCTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGGCC
AGCAACACCAAGGTGGACAAGAGAGTTGAGCCAAATCTTGTGACAA
AACTCACACATGCCAACCGTGCCAGCACCTGAACACTCCTGGGGGACC
GTCAGTCTTCCTCTTCCCCAAAACCCAAGGACACCCCTCATGATCTCC
CGGACCCCTGAGGTACATGCGTGGTGGACGTGAGCCACGAAGA
CCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAA
TGCCAAGACAAAGCCGGAGGAGCAGTACAACAGCACGTACCGTG
TGGTCAGCGTCCTCACCGTCTGCACCAGGACTGGCTGAATGGCAAGG
AGTACAAGTGCAGGTCTCAACAAAGCCCTCCCAGCCCCATCGAG
AAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCCACAGGTGTA
CACCCCTGCCCATCCGGAGGAGATGACCAAGAACCCAGGTGAGCC
TGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATGCCGTGGAGT
GGGAGAGCAATGGGCAGCCGGAGAACAAACTACAAGAACCCACGCC
GTGCTGGACTCCGACGGCTCCTCTTCTACAGCAAGCTCACCGTG
GACAAGAGCAGGTGGCAGCAGGGAACGTCTCATGCTCCGTGAT
GCATGAGGCTCTGCACAACCAACTACACCGCAGAAGAGGCCTCTCC
TCCGGGTAAATGA

FIGURE 3C: A schematic representation of the heavy chain of antibody hB7V3V2-hG1.

TCTGGGATGGAGCCGGATCTTCTCTCTCTGTCAATATTGCGGTGTCCTTGCCAGGTCAGCTGCAACAGTCTGGATCTGAGCTGAAGAAGCCTGGGCTTCAGTGAAGATCTC 5160
 M G W S R I F L F L L S I A G V H C Q V Q L Q Q S G S E L K H K P G A S V K I S
 leader **hB7V3 Vh**
 CTGCAAGGCTCTGGTATTCACTGACTACATCATACTCTGGGTGAGGCAAGACCTCTGAAAGGGCTTCTAGTGGATTGGACATATTGTATCTTACTATGGTAGTCTAACTACAA 5280
 C K A S G Y S F T D Y I I L W V R Q N P G K G L E W I G H I D P Y Y G S S N Y N
hB7V3 Vh
 TCTGAAATTCAAGGGCAGAGTGACAATCACCGCAGGACAGTCTACATGGAGCTCTCAGTCAGATCTGGAGGACACTGCACTGAGCTTAACTGTGGAAGCTAAGAG 5400
 L K F K G R V T I T A D Q S T T T A Y M E L L S S L R S E D T A V Y Y C G R S K R
hB7V3 Vh
 GGACTACTTGTACTGGGGCAAGGCACACTCTCACAGTTCTCTCAGGCTCAGGCCCCATCGCTTCCCGCTAGCACCCCTCTCAAGAGCACCTCTGGGGCAAGCGGC 5520
 D Y F D Y W G Q G T T L T V S S A S T K G P S V F P L A P S S K S T S G G T A A
hB7V3 Vh **hG1**
 CCTGGGTGCTGGTCAAGGACTACTCTCCCGAACCGTGACGGTGCTGGAACTCAGGGCCCTGACCAGCGGCGTGCACACCTCCGGCTGCTCTAGCTCCTAGACTC 5640
 L G C L V K D Y F P E P V T V S W N S G A L T S G V H T F P A V L Q S S G L Y S
hG1
 CCTCAGCAGCGTGGTGAACGGCTGGCTCACAGCTGGGACCCAGACCTACATCTGCAACGGTAATCACAGGCCAGCAGAACCAAGGTGGCAAGAGAGTTGAGCC 5760
 L S S V V T V P S S S L G T Q T Y I C N C V N H N K P S N T K V D K R V E P K S C D
hG1
 CAAAACTCACACATGCCAACCGTGGCCAGCACCTGAACCTCTGGGGGAGCGTAGCTCTCTCTTCCCGAACCCAAAGGACACCTCTAGTATCTCCGGACCCCTGAGGTC 5880
 K T H T C P P C P A P E L L G G P S V F L F P P K P K D T L M I S R T P E V T C
hG1
 CGTGGTGTGGACGTGAGCCACGAAAGACCTGGTAGGTCAAGTTCACGGTACGGTACGGTGGCTAGCATATGCCAAGAACAGGCCGGGGAGGAGCAGTACACAGCGTACGG 6000
 V V V D V S H E D P E V K F N W Y V D G G V E V H N A K T K P R E E Q Y N S T Y R
hG1
 TGTGGTCAAGCTCTACCGCCAGGACTGGCTGAATGGCAAGGGTAGCAAGTGCAGGTCTCAACAAAGCCCTCCAGCCCCCATCGAGAAAACCATCTCAAGGCCAAGG 6120
 V V S V L T V L H Q D W L N G K E Y K C K V S N K A L P A P I E K T I S K A K G
hG1
 GCAGCCCCGAGAACACCAGGTGACACCTGGCCCATCGGGAGGAGATGACAGAACAGGTGAGCTGCACCTGCTGGTCAAGGCTTCTATCCCAAGGACATCGCCGGAGT 6240
 Q P R E P Q V Y T L P P S R E E M T K N Q V S L T C L V K G F Y P S D I A V E W
hG1
 GGAGAGCAATGGCAGCGGAGAACATACAGAACAGCCCTCCGGTGCTGGACCTGGCTCAGGCTCCCTCTCTACAGCAAGTCACCGTGGCAAGAGCAGGGAG 6360
 E S N G Q P E N N Y K T T P P V L D S D G S F F L Y S K L T V D K S R W Q Q G N
hG1
 CGTCTCTCATGCTCCGTGATGCAAGGGCTCTGCACACCAACTACAGCAGAGAACAGCTCTCTCTGGTCAAGGAGTAAATGAA 6442
 V F S C S V M H E A L H N H Y T Q K S L S L S P G K .
hG1

FIGURE 3D

Light Chain (human Ck) (SEQ ID NO. 18)

MDMRVSAQLG₁₁WLSGARCDIQMTQSPSSLSASIGDRV₁₆TITCKASQD
INSYLSWFQQKPGKAPK₁₁YRANRLVDGVP₁₆SRFGSGSGT₁₆DYTLT₁₁SSLQ
PEDFAVYYCLQYDEFPYTFGGGT₁₁KLEIKRTVAAPS₁₆VIFPPSDEQLKSGT
ASVVCLLN₁₁NFYPREAKVQWKVDNALQSGNSQESVTEQDSKD₁₁STYSL₁₁
STLTLSKADYEKHKVYACEVTHQGLSSPVT₁₆KSFNRGEC

FIGURE 3E**(SEQ ID NO. 19)**

ATGGACATGAGGGTCTCTGCTCAGCTCCTGGGCTCCTGCTGCTCTGG
CTCTCAGGGGCCAGGTGTGACATCCAGATGACACAGTCTCCATCTTCC
CTGTCTGCATCTATAGGAGACAGAGTCACTATCACTTGCAGGCGAGT
CAGGACATTAATAGCTATTAAGCTGGTCCAGCAGAAACCAGGGAA
AGCTCCTAACAGCTGCTGATCTATCGTCAAACAGATTGGTAGATGGGT
TCCATCAAGGTTCACTGGCAGTGGATCTGGACAGATTATACTCTCAC
CATCAGCAGCCTGCAGCCTGAAGATTGCAGTTATTATTGTCTACA
GTATGATGAGTTCCGTACACGTTGGAGGGGGACCAAGCTGGAAAT
AAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCGCCATCTGAT
GAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGCCTGCTGAATAAC
TTCTATCCCAGAGAGGCCAAAGTACAGTGGAAAGGTGGATAACGCCCTC
CAATCGGGTAACTCCCAGGAGAGTGTACAGAGCAGGACAGCAAGGA
CAGCACCTACAGCCTCAGCAGCACCTGACGCTGAGCAAAGCAGACT
ACGAGAAACACAAAGTCTACGCCCTGCGAAGTCACCCATCAGGGCCTG
AGCTCGCCCGTCACAAAGAGCTCAACAGGGAGAGTGTAG

FIGURE 3F: A schematic representation of the light chain of antibody hB7V3V2-hG1.

TTCCATGGTCTTTCTGCAGTCACCGTCCTGACACGAAGCTGCCACCATGGACATGAGGGTCTCTGCTCAGCTCCGGCTCCTGCTCTGGCTTCAGGGCAGGT 11400
 M D M R V S A Q L L G L L L W L S G A R C
 leader

GACATCCAGATGACACAGTCTCCATCTTCCCTGTCGATCTATAGGAGACAGAGTCACTATCACTTGCAAGGGAGTCAGGACATTAATAGCTATTAAGCTGGTTCCAGCAGAAACCA 11520
 D I Q M T Q S P S L S A S I G D R V T I T C K A S Q D I N S Y L S W F Q Q K P
 V2VK

Psrl

GGAAAGCTCTAACGCTGCTGATCTATCGCAAACAGATTGGTAGATGGGGTCCATCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTATACTCTCACCATCAGCAGCCTGCAGCCT 11640
 G K A P K L L I Y R A N R L V D G V P S R F S G S G S G T D Y T L T I S S L Q P
 V2V

BsmI

GAAGATTCGAGTTTATATTGCTCACAGTATGAGTTCCGTACACGTTGGAGGGGGGACCAAGCTGGAAATAAACGTAACGGTGGCTGCACCATCTGTCTTCATCTCCCGCCA 11760
 E D F A V Y Y C L Q Y D E F P Y T F G G G T K L E I K R T V A A P S V F I F P P
 V2V

hCk

TCTGATGAGCAGTTGAAATCTGAACTGCCCTGTTGTGCGCTGCTGATAATAACTTCTATCCCAGAGGGCCAAAGTACAGTGGAAAGGTGGATAACGCCCTCCAATCGGGTAACCTCCAG 11880
 S D E Q L K S G T A S V V C L L N N F Y P R E A K V Q W K V D N A L Q S G N S Q
 hCk

GAGAGTGTACAGAGCAGGACAGCACCAAGGACAGCACCTACAGCCTCAGCACCCCTGACGCTGACAAAGCAGACTACGAGAAAACACAAGTCTACGCCCTGCGAAGTCACCCATCAGGGC 12000
 E S V T E Q D S K D S T Y S L S S T L T L S K A D Y E K H K V Y A C E V T H Q G
 hCk

CTGAGCTGCCGTCAAAAGAGCTTCAACAGGGAGAGTAG 12045
 L S S P V T K S F N R G E C .

hCk

FIGURE 4A-4F

FIGURE 4A**hB7V3V2-hG2G4****Heavy chain (SEQ ID NO. 21)**

MGWSRIFLFLLSIIAGVHCQVQLQQSGSELKKPGASVKISCKASGYSFTDY
IILWVRQNPKGKGLEWIGHIDPYYGSSNYNLKFGRVTITADQSTTAYME
LSSLRSEDTAVYYCGRSKRDYFDYWGQGTTLVSSASTKGPSVFPLAPC
SRSTSESTAALGCLVKDYFPEPVTVWSWNSGALTSGVHTFPAVLQSSGL
YSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCP
APPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYV
DGVEVHNAKTKPREEQFNSTYRVSVLTVLHQDWLNGKEYKCKVSN
KGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFY
PSDIAVEWESNGQPENNYKTPPPVLDSDGSFFLYSRLTVDKSRWQEG
NVFSCSVMHEALHNHYTQKSLSLSLGK

FIGURE 4B**(SEQ ID NO. 22) (genomic sequence hG2G4)**

ATGGGATGGAGCTGTATCATCCTCTTGGTAGCAACAGCTACAGGTGTCCACTCCCTCGAG
GTCCAGCTGCAACAGTCTGGACCTGAGCTGGTAAGCCTGGGCTTCACTGAAGATGTCCTGC
AAGGCTCTGGTTATTCACTCACTGACTACATCATACTCTGGGTGAAGCAGAACCATGGAAAG
AGCCTTGAGTGGATTGGACATATTGATCCTTACTATGGTAGTTCAACTACAATCTGAAATTCA
AGGGCAAGGCCACATTGACTGTAGACAAATCTTCAGCACAGCCTACATGCAGCTAACAGT
CTGACATCTGAGGACTCTGCAGTCTATTACTGTGGAAGATCTAAGAGGGACTACTTGACTAC
TGGGCCAAGGCACCACTCTCACAGTTCCAGCAGCCTCCACCAAGGGCCATCCGTCTTCCCC
CTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCGTGGTCAAGGA
CTACTTCCCCAACCGGTGACGGTGTGTTGAACTCAGGCCCTGACCAGCGCGTGCACAC
CTTCCCGCTGCTCACAGTCTCAGGACTCTACTCCCTCAGCAGCGTGGTACCCTGCCCTCC
AGCAACTTCGGCACCCAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGT
GGACAAGACAGTTGGTGAGAGGCCAGCTCAGGGAGGGAGGGTCTGCTGGAAGCCAGGCTC
AGCCCTCCTGCCCTGGACGCACCCCGCTGTGCAGCCCCAGCCCAGGGCAGCAAGGCAGGCC
CATCTGTCTCCTCACCGGAGGCCTCTGCCGCCACTCATGCTCAGGGAGAGGGTCTTCTG
GCTTTTCCACCAGGCTCCAGGCAGGCACAGGCTGGGTGCCCTACCCAGGCCCTCACACA
CAGGGCAGGTGCTGGCTCAGACCTGCCAAAGCCATATCGGGAGGACCCCTGCCCTGAC
CTAAGCCGACCCCAAAGGCCAAACTGTCCACTCCCTCAGCTCGACACCTCTCTCCCTCCAG
ATCCGAGTAACCTCCAACTTCTCTGCAGAGCGCAAATGTTGTGTCAGTGCCCACCGTGC
CCAGGTAAGCCAGCCCAGGCCCTGCCCTCCAGCTCAAGGCAGGACAGGTGCCCTAGAGTAGC
CTGCATCCAGGGACAGGCCAGCTGGGTGCTGACACGTCCACCTCCATCTTCCCTCAGCAC
CACCTGTGGCAGGACCGTCAGTCTTCCCTTCCCCAAAACCCAAGGACACCCCTCATGATCT
CCCGGACCCCTGAGGTACGTGCGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAG
TTCAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGGGAGGAGCA
GTTCAACAGCACGTACCGTGTGGTACGCGTCCACCGTCTGCACCCAGGACTGGCTGAACGG
CAAGGAGTACAAGTCAAGGTCTCCAACAAAGGCCTCCGTCTCCATCGAGAAAACCATCT
CCAAAGCCAAAGGTGGACCCACGGGTGCGAGGCCACATGGACAGAGGTAGCTCGGCC
ACCCCTGCCCTGGAGTGACCGCTGTGCCAACCTCTGCCCTACAGGGCAGCCCCAGAGCC
ACAGGTGTACCCCTGCCCTACCCAGGAGGAGATGACCAAGAACCCAGGTAGCCTGACCT
GCCTGGTCAAAGGCTTCTACCCAGCGACATCGCCGTGGAGTGGAGAGCAATGGCAGCCG
GAGAACAACTACAAGACCCACGCCCTCCGTGGACTCCGACGGCTCCTTCTCCTACAGC
AGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGAAATGTCTTCTCATGCTCCGTGATGCA
TGAGGCTCTGCACAACCACTACACACAGAACGCTCCCTGTCTGGTAAATGATGA

FIGURE 4C: A schematic representation of the heavy chain of antibody hB7V3V2-hG2G4.

CTACAGACATAATAGCTGACAGACTAACAGACTGTTCTTCCATGGGCTTCTGAGCTACCGCCTTGACAGCAAGCTGGCCACCATGTTGGGATGGAGCCGGATCTTCTCTTC 2280
 L L S I I A G V H C Q V Q L Q Q S G S E L K K P G A S V K I S C K A S G Y S F T
 leader
 V3Vh
 GACTACATACATCTGGGTGAGGAGAAGCCCTGGAAAGGGCTTGAGTGGATTGGACATATTGATCTTACTATGGTAGTCTAATCTGAAATTCAGGGCAGAGTGAACATC 2520
 D Y I I L W V R Q N P G K G L E W I G H I D P Y Y G S S N Y N L K F K G R V T I
 V3Vh
 ACCGGCAGCCAGTCTACACCACAGCTACATGGGCTCTCCAGTCTGAGAGTCTGAGGACACTGCGACTTACTCTGGAAAGATCTAAGAGGAGACTACTTGGACTCTGGGCAAGGC 2640
 T A D Q S T T A Y M E L S S L R S E D T A V Y Y C G R S K R D Y F D Y W G Q G
 V3Vh
 ACCACTCTCACAGTCTGGCTCAGGCCCAAGGGCCATCCGCTTCCCCCTGGCCCTGCTCCAGGAGCACCTCCAGAGCCACGCTGGACTCTGGCTGGCTCAAGGACTACTTC 2760
 T T L T V S S A S T K G P S V F P L A P C S R S T S E S T A A L G C L V K D Y F
 G2G4CH1
 V3Vh
 BseII
 CCCGAAACGGTGACGGTGCTGGAACTCAGGGCCCTGACCGCGCTGACACCTCCGGCTGCTCACAGTCTACAGGACTCTACCCCTCAGCGCTGTGACCGTGCCTCC 2880
 P E P V T V S W N S G A L T S G V H T F P A V L Q S S G L Y S L S S V V T V P S
 G2G4CH
 AGCACTTGGCACCCAGACTACACCTGCAACGGTAGATACAAGGCCAGCACACCAAGGGTGACAAGAGCTGGTGAGAGGCCAGTCAGGGAGGGGGTCTGCTGGAAAGCCAG 3000
 S N F G T Q T Y T C N V D H K P S N T K V D K T V I
 G2G4CH1
 GCTCAGCCCTCTGGCTGGACCCACCCGGCTGCTCACGGCCAGGGCAGGGCAGGGCCATCTGCTTCCCTACCCGGAGGCCCTGCCCCCCTACATGGCTCAGGGAGAG 3120
 GGTCTTCTGGCTTTTCCACGGCTCCAGGCCAGGGCTGGTGCCCCCTACCCAGGGCCATCACAGGGCTGGCTTGGCTCAGACCTGGCAAGGGCTTGGCTCAGACCTGGCAAAGGCCATATCGGGAGG 3240
 ACCCTGGCCCTGACCTAACGGCACCCAAAGGCCAACACTGTCCACTCCCTCAGCTCGGACACCTTCTCCCTCCAGATCGGAGTAACCTCCAAATCTCTCTGCGAGGCCAAATGGT 3360
 E R K C
 Hinge
 GTGTCGAGTGCCCACCGTGGCCAGGTAAGCCAGGCCAGGCTCGCCCTCAGCTCAAGGCGGGACAGGTGGCTAGAGTAGGCTGATCCAGGGACAGGCCAGCTGGGTGCTGACACG 3480
 C V E C P P C P
 Hinge
 PmII
 TCCACCTCCATCTTCTCTCAGCACACCTGTGGCAGGACCGTCAGTCTCTCTTCCCCAAACCCAGGACACCCCTCATGATCTCCGGACCCCTGAGGTACGGCTGGTGGTGGT 3600
 A P P V A G P S V F L F P P K P K D T L M I S R T P E V T C V V V
 CH2
 GACGTGAGGCCAGGAAGCCCGAGGTCGAGTTCACATGGTAGCTGGATGGCTGGAGGTGCATAATGGCAAGGAAAGCAGGGGGAGGAGCAGTCAACAGCAGCTACCCCTGTCAGC 3720
 D V S Q E D P E V Q F N W Y V D G V E V H N A K T K P R E E Q F N S T Y R V V S
 CH2
 GTCTCACCGCTCTGACCAAGGACTGGCTGAACGGCAAGGGATAAAGTGCAGGCTCCAAAGGCCCTCCGTCCTCATCGAGAAAACATCTCCAAAGGCCAAAGGTGGGACCCAC 3840
 V L T V L H Q D W L N G K E Y K C K V S N K G L P S S I E K T I S K A K
 CH2
 DrIII
 PstI
 GGGGTGCGAGGGCACATGGACAGAGGTAGCTCGGCCACCCCTGCCCCGGAGTACCGCTGTGCCACCTCTGTCCTACAGGGAGGCCAGGGAGTGTACACCCCTGCC 3960
 G Q P R E P Q V Y T L P
 G2G4Ch
 CCCATCCCAGGAGGAGTGCACAGAACCGTCAGGCTGACCTGCTGGTCAAAGGTTCTACCCAGCGACATGCCGTGGAGTGAGGACATGGGACAGGGAGAACACTACAA 4080
 P S Q E E M T R N Q V S L T C L V K G F Y P S D I A V E W E S N G Q P E N N Y K
 G2G4Ch3
 GACACGGCTCCCTGCTGGACTCCGACGGCTCTCTCTCTCATACAGCAGGCTAACCGTGGACAGAGCAGGTGGAGGGGGATGTTCTCATGCTCCGGATGTCATGGGGCT 4200
 T T P P V L D S D G S F F L Y S R L T D K S R W Q E G N V F S C S V M H E A L
 G2G4Ch3
 GCACAAACCTACACACAGAGAGGCCCTCCCTGTCCTGGATAATGAGAGATTCAATTGATCATATACTGGAGGTTTACTTGCTTAAACCTCCAC 4320
 H N H Y T Q K S L S L S L G K . . .
 G2G4Ch3

FIGURE 4D**Light Chain (human Ck) (SEQ ID NO. 24)**

MDMRVSAQLLGLLLWLSGARCDIQMTQSPSSLSASIGDRVVTITCKASQD
INSYLSWFQQKPGKAPKLLIYRANRLVDGVPSRFSGSGSGTDYTLTISSLQ
PEDFAVYYCLQYDEFPYTFGGKTLEIKRTVAAPSVFIFPPSDEQLKSGT
ASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLS
STLTLSKADYEHKVYACEVTHQGLSSPVTKSFNRGEC

FIGURE 4E**(SEQ ID NO. 25)**

ATGGACATGAGGGTCTCTGCTCAGCTCCTGGGGCTCCTGCTGCTCTGG
CTCTCAGGGGCCAGGTGTGACATCCAGATGACACAGTCTCCATCTCC
CTGTCTGCATCTATAGGAGACAGAGTCACTATCACTTGCAAGGCGAGT
CAGGACATTAATAGCTATTAAAGCTGGTCCAGCAGAAACCAGGGAA
AGCTCCTAACAGCTGCTGATCTATCGTCAAACAGATTGGTAGATGGGGT
TCCATCAAGGTTCACTGGCAGTGGATCTGGACAGATTATACTCTCAC
CATCAGCAGCCTGCAGCCTGAAGATTGCAGTTATTATTGTCTACA
GTATGATGAGTTCCGTACACGTTGGAGGGGGACCAAGCTGGAAAT
AAAACGTACGGTGGCTGCACCCTGTCTTCATCTTCCGCCATCTGAT
GAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGCCTGCTGAATAAC
TTCTATCCCAGAGAGGCCAAAGTACAGTGGAAAGGTGGATAACGCCCTC
CAATCGGGTAACTCCCAGGAGAGTGTACAGAGCAGGACAGCAAGGA
CAGCACCTACAGCCTCAGCAGCACCTGACGCTGAGCAAAGCAGACT
ACGAGAAACACAAAGTCTACGCCCTGCGAAGTCACCCATCAGGGCCTG
AGCTCGCCCGTCACAAAGAGCTTCAACAGGGAGAGTGTAG

FIGURE 4F: A schematic representation of the light chain of antibody hB7V3V2-hG2G4.

TTCCCATGGGCTTTCTGCAGTCACCGTCCCTGACACGAAAGCTGGCCACCATGGACATGAGGGTCCTGCTCAGCTCAGCTGGGCTCTGCTGCTGGCTCTAGGGCCAGGTG 11400
 M D M R V S A Q L L G L L L L W L S G A R C
 leader

GACATCCAGATGACACAGTCTCCATCTCCCTGCTGCACTTATAGGAGACAGAGTCACTATCACTTGCAGGGCAGTCAGGACATTTAAGCTGGTCCAGCAGAAACCA 11520
 D I Q M T Q S P S S L S A S I G D R V T I T C K A S Q D I N S Y L S W F Q Q K P
 V2V
 PstI

GGAAAGCTCTTAAGCTGCTGATCTATCGTCAAACAGATTGGTAGATGGGGTCCATCAAGGTTCAAGTGGCAGTGGATCTGGGACAGATTATAAGCTGGTCCAGCAGAAACCA 11640
 G K A P K L L I Y R A N R L V D G V P S R F S G S G S G T D Y T L T I S S L Q P
 V2V
 PstI

GAAGATTTCCGAGTTTATTATGTTCTACAGTATGAGTTCCGTACACGTTGGAGGGGACCAAGCTGAAATAAACGTAACGGTGGCTGCACCATCTGCTTCATCTCCGCCA 11760
 E D F A V Y Y C L Q Y D E F P Y T F G G G T K L E I K R T V A A P S V F I F P P
 V2V
 hCk

TCTGATGAGCAGTGAAATCTGAACTGCCCTGTTGTGCGCTGCTGAAATAACCTCTATCCAGAGGGCCAAAGTACAGTGGAAAGGTGGATAACGCCCTCAATGGGTAACCTCCAG 11880
 S D E Q L K S G T A S V V C L L N N F Y P R E A K V Q W K V D N A L Q S G N S Q
 hCk

GAGAGTGTACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTAGCGACGCCCTGACGCTGAGCAAGCAGACTACGAGAAACACAAAGTCTACGCCCTGGAAGTCACCCATCAGGGC 12000
 E S V T E Q D S K D S T Y S L S S T L T L S K A D Y E K H K V Y A C E V T H Q G
 hCk

CTGAGCTGCCGTACAAGAGCTCAACAGGGAGAGTGTAG 12045
 L S S P V T K S F N R G E C .
 hCk

FIGURE 5

Cell surface expression of CD200 on human CD3+ cells following activation with mOKT3





FIGURE 6

Human T cells activated through T cell receptor signaling serve as sensitive targets for anti-CD200 mediated ADCC

A.



B.






FIGURE 7A



HD=high dose, LD=low dose, LT=long-term, ST=short-term

*Animals were sacrificed at the endpoint of rejection.

FIGURE 7B



HD=high dose, LD=low dose, LT=long-term, ST=short-term

*Animals were sacrificed at the endpoint of rejection.

FIGURE 8




FIGURE 9A

**Comparison of Cell Populations in Mouse Heart Allograft Recipients
(OX90 Project)**




FIGURE 9B




FIGURE 9C




FIGURE 10

1 EVQLVESGGGLVKPGRSLKLSCHAASGFTFSDYYMAWVRQAPKKGL OX90NE
 1 EVQLVESGGGLVKPGRSLKLSCHAASGFTFSDYYMAWVRQAPKKGL OX90mG2a

 46 EWVASIGYEGTSTYYGDSVKGRFTISRDNAKSTLYLQMNSLRSED OX90NE
 46 EWVASIGYEGTSTYYGDSVKGRFTISRDNAKSTLYLQMNSLRSED OX90mG2a

 91 TATYYCTRLELAGVMDAWGQGASVTVSSAKTTAPSVDVYPLAPVCGD OX90NE
 91 TATYYCTRLELAGVMDAWGQGASVTVSSAKTTAPSVDVYPLAPVCGD OX90mG2a

 136 TTGSSVTLGCLVKGYFPEPVLTWNSGSLSSGVHTFPAVLQSDLY OX90NE
 136 TTGSSVTLGCLVKGYFPEPVLTWNSGSLSSGVHTFPAVLQSDLY OX90mG2a

 181 TLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPC OX90NE
 181 TLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPC OX90mG2a

 226 PPCKCPAPNL**E**GGPSVFIFPPKIKDVLMISSPIVTCVVVDVSED OX90NE
 226 PPCKCPAPNL**L**GGPSVFIFPPKIKDVLMISSPIVTCVVVDVSED OX90mG2a

 271 DPDVQISWFVNNVEVHTAQQTQTHREDYNSTLRVVSALPIQHQDW OX90NE
 271 DPDVQISWFVNNVEVHTAQQTQTHREDYNSTLRVVSALPIQHQDW OX90mG2a

 316 SGK**A**F**A**CAVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEMT OX90NE
 316 SGK**E**F**K**CKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEMT OX90mG2a

 361 KKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSY OX90NE
 361 KKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSY OX90mG2a

 406 FMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTKSFRTGK OX90NE
 406 FMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTKSFRTGK OX90mG2a

FIGURE 11

